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Abstract
Patient-based cancer models are essential tools for studying tumor biology and for the assessment of drug responses in a trans-
lational context. We report the establishment a large cohort of unique organoids and patient-derived orthotopic xenografts 
(PDOX) of various glioma subtypes, including gliomas with mutations in IDH1, and paired longitudinal PDOX from primary 
and recurrent tumors of the same patient. We show that glioma PDOXs enable long-term propagation of patient tumors and 
represent clinically relevant patient avatars that retain histopathological, genetic, epigenetic, and transcriptomic features of 
parental tumors. We find no evidence of mouse-specific clonal evolution in glioma PDOXs. Our cohort captures individual 
molecular genotypes for precision medicine including mutations in IDH1, ATRX, TP53, MDM2/4, amplification of EGFR, 
PDGFRA, MET, CDK4/6, MDM2/4, and deletion of CDKN2A/B, PTCH, and PTEN. Matched longitudinal PDOX recapitu-
late the limited genetic evolution of gliomas observed in patients following treatment. At the histological level, we observe 
increased vascularization in the rat host as compared to mice. PDOX-derived standardized glioma organoids are amenable to 
high-throughput drug screens that can be validated in mice. We show clinically relevant responses to temozolomide (TMZ) 
and to targeted treatments, such as EGFR and CDK4/6 inhibitors in (epi)genetically defined subgroups, according to MGMT 
promoter and EGFR/CDK status, respectively. Dianhydrogalactitol (VAL-083), a promising bifunctional alkylating agent in 
the current clinical trial, displayed high therapeutic efficacy, and was able to overcome TMZ resistance in glioblastoma. Our 
work underscores the clinical relevance of glioma organoids and PDOX models for translational research and personalized 
treatment studies and represents a unique publicly available resource for precision oncology.
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Introduction
Candidate therapeutics for personalized treatment in rare 
tumors are difficult to test in clinical trials because of inter-
tumor differences and the limited number of patients repre-
senting specific genetic profiles. Adult diffuse gliomas are a 
particularly heterogeneous group of rare brain tumors, with 
grade IV glioblastoma (GBM) being the most malignant sub-
type [67]. Despite surgery, radiotherapy and chemotherapy, 
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the median survival of GBM patients is 14 months, and the 
recurrence is inevitable. GBM, characterized as Isocitrate 
dehydrogenase wild type (IDHwt), encompasses tumors 
with varying genetic backgrounds that affect distinct signal-
ing networks [11, 14]. They can be classified into molecular 
subtypes with differing expression signatures [107, 112], 
display variable DNA ploidy [92] and have different DNA 
methylation status of the O-6-methylguanine-DNA meth-
yltransferase (MGMT) gene promoter. The latter has been 
shown to predict the response to temozolomide (TMZ) [48], 
the standard-of-care chemotherapeutic agent approved for 
GBM [94]. A separate group of adult diffuse gliomas char-
acterized by activating IDH1 (IDH1mut) or IDH2 (IDH-
2mut) mutations comprise 1p/19q intact astrocytomas and 
1p/19q co-deleted oligodendrogliomas, with varying grades 
(II-IV) and survival rates [89], further displaying, e.g., PDG-
FRA and CDK4 amplification, CDKN2A/B deletion, ATRX, 
TP53, or TERT promoter mutations [60, 83, 116], as well as 
a glioma CpG Island Methylator Phenotype (G-CIMP) [33, 
79]. Several studies point towards an evolution of diffuse 
gliomas upon treatment and recurrence, where IDH1/2mut 
astrocytomas show most and IDHwt GBMs least changes in 
relapsed tumors [5, 29, 38, 57]. Still, most identified changes 
appear idiosyncratic and it remains unclear to what extent 
the current standard treatment leads to molecular changes 
that could affect drug responses for precision medicine. So 
far, all targeted treatment attempts in gliomas, e.g., targeting 
EGFR [41], have failed in clinical trials and effective treat-
ment strategies are urgently needed.
A major reason for the numerous failures of clinical 
trials is the large gap between preclinical models and the 
treatment situation in patients where the existing preclini-
cal models inaccurately represent human disease. Robust 
brain tumor models, able to reliably predict the sensitivity 
of novel personalized treatments in a molecularly defined 
group of patients, represent an unmet need [2]. For many 
years, the glioma research community relied on a handful of 
long-term adherent GBM cell lines that undergo significant 
genetic drift. In vivo such cell lines do not recapitulate cer-
tain histopathological features of patient tumors and display 
inadequate treatment outcomes [32, 34, 103]. Some of these 
shortcomings can be avoided by growing cells in defined 
serum-free conditions as 3D tumor spheres, adapted from 
neural stem/progenitor cultures (generally referred to as gli-
oma stem cell (GSC) or brain-tumor initiating cell (BTIC) 
cultures) [18, 62]. However, these are generally limited to 
classical GBM [4] and still suffer from a loss of clonal heter-
ogeneity and molecular adaptations to culture conditions [6, 
88], in particular loss of focal amplifications related to high 
growth factor supply in the medium [66]. Patient-derived 
GBM organoids derived in serum-free conditions appear as 
a robust in vitro alternative, with a very good preservation 
of a heterogeneous tissue structure [49, 51]. However, their 
use is restricted by the limited availability of starting mate-
rial (large amount of en bloc tissue required [51]), which is 
hardly compatible with modern neurosurgical practice of 
ultrasonic aspiration, and continuous passaging in vitro may 
lead to selection of proliferative GBM tumor cells. For sev-
eral cancer types patient-derived xenografts (PDXs) estab-
lished subcutaneously in immunodeficient animals brought 
a noteworthy advance, as they allow for propagation of pri-
mary patient tumors in less selective conditions and retain 
interactions with nonmalignant cells [16]. PDXs were shown 
to be more accurate in predicting treatment responses than 
common cell lines [46]. Several international initiatives, 
such as the EurOPDX and PDXNet consortia, now develop 
and standardize PDXs for preclinical studies [42, 72]. How-
ever, a recent evaluation of GBM PDXs highlighted draw-
backs in retaining chromosomal copy number alterations 
(CNAs) [7], and it remains to be seen whether they repre-
sent a sustainable model for testing precision medicine regi-
mens. As subcutaneous PDXs do not recapitulate the natural 
tumor microenvironment (TME), patient-derived orthotopic 
xenografts (PDOX) implanted directly in the brain may be 
more adequate for modeling gliomas in their natural milieu, 
preserving the physical and physiological constraints of the 
blood–brain barrier and the cerebrospinal fluid. To test this, 
it is important to assess whether PDOXs can recapitulate 
patient-specific genetic and epigenetic features, transcrip-
tomic programs and intratumoral heterogeneity prior and 
after treatment, making them amenable as patient avatars 
for preclinical precision medicine.
We have previously reported that short-term culture of 
mechanically dissociated GBM tissue fragments allows 
for derivation of self-organizing 3D organoids, previously 
referred to as organotypic spheroids, which preserve tissue 
structure, intercellular connections, and TME components 
[10, 26]. Intracranial implantation of such GBM organoids 
in the brain of immunodeficient rodents allowed for con-
servation of tumor DNA ploidy and major histopathologi-
cal features, such as angiogenesis and invasiveness [12, 
86, 92, 97, 111]. Such GBM PDOXs recapitulate clinical 
responses towards antiangiogenic agents [1, 53]. Here, we 
provide systematic evidence that organoid-based glioma 
PDOXs are reproducible and clinically relevant models for 
functional precision medicine. By combining tumor orga-
noids of various glioma subtypes with in vivo expansion 
in the brain microenvironment, we present a cohort of 40 
PDOX generated from primary and paired recurrent gliomas 
with mixed genetic backgrounds including, among others, 
IDH1 mutation and distinct EGFR variants. We show that 
these PDOXs preserve key histopathological structures of 
malignant gliomas (grade III/IV), recapitulate tumor-intrin-
sic genetic and molecular features at the individual patient 
level and retain intratumoral transcriptomic programs and 
stem-cell-associated heterogeneity. This also applies to our 
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unique selection of matched PDOX from paired recurrent 
glioma samples. We further show that glioma organoids 
and PDOXs represent adequate patient avatars for precision 
oncology, also in a high-throughput manner. Drug testing in 
3D organoids allows for screening in vitro at reasonable cost 
with clinically-relevant responses, which can be further vali-
dated in vivo. Lastly, we highlight the promising therapeutic 
potential of dianhydrogalactitol (VAL-083), a bifunctional 
alkylating agent, for treatment of GBM. In summary, our 
PDOX live biobank represents an important resource for 
accelerating the development of novel treatment strategies 
for glioma patients.
Materials and methods
Clinical samples, organoid, and PDOX derivation
Glioma samples were collected at the Centre Hospitalier 
of Luxembourg (CHL; Neurosurgical Department) from 
patients having given informed consent, and with approval 
from the local research ethics committee (National Com-
mittee for Ethics in Research (CNER) Luxembourg). For 
patient information see Supplementary Table  1, online 
resource. Small pieces of tissue were flash frozen for further 
molecular analysis. If enough tumor material was obtained, 
3D organoids from patient samples were prepared as pre-
viously described [12]. Briefly, mechanically minced fresh 
human glioma tissue pieces, without enzymatic digestion, 
were seeded on agar coated flasks (0.85%) and allowed to 
self-organize and form organoids (previously called organo-
typic spheroids) for up to 2 weeks at 37°C under 5%  CO2 
and atmospheric oxygen in DMEM medium, 10% FBS, 2 
mM L-Glutamine, 0.4 mM NEAA, and 100 U/ml Pen–Strep 
(all from Lonza). Organoids (generation 0) with a diam-
eter of 300-1000 µm were then implanted in the brain of 
immunodeficient mice (NOD/Scid or NSG; 6 organoids 
per mice) using a Hamilton syringe (Hamilton, Reno, NV, 
USA). Animals (generation 1) were maintained under SPF 
conditions and sacrificed at the appearance of neurological 
(locomotor problems, uncontrolled movements) or behav-
ioral abnormalities (prostration, hyperactivity) and weight 
loss. Optionally tumor volume was monitored by MRI. 
Organoids (generation 1) were further prepared from minced 
xenografted brains in the same way as for patient tissue and 
serially implanted for several generations. No mechanical 
and enzymatic digestion was performed prior implantation. 
A PDOX model was considered to be established at genera-
tion 3, when tumor phenotype and animal survival appeared 
stable. For specific purposes, experiments were performed 
in nude mice and/or eGFP expressing NOD/Scid mice [78]. 
Samples P8, P13 and P3 were obtained from Haukeland 
University Hospital (Bergen, Norway) following approval 
of the local ethics committee (approval number 2009/117). 
For these samples, organoids were initially implanted into 
the brain of nude rats (rnu; 10 organoids per rat: P3, P8, P13 
models). Kaplan–Meier survival curves were produced in 
GraphPad with Wilcoxon signed-rank statistical test. The 
handling of animals and the surgical procedures were per-
formed in accordance with the regulations of the European 
Directive on animal experimentation (2010/63/EU) and the 
Norwegian Animal Act, i.e., the experimental protocols were 
approved by the local ethics committee (Animal Welfare 
Structure of the Luxembourg Institute of Health; protocols 
LRNO-2014-01, LUPA2019/93, and LRNO-2016-01) and 
by the Luxembourg Ministries of Agriculture and of Health. 
PDOX models are available from the corresponding author 
or via EuroPDX consortium (https ://www.europ dx.eu/) and 
PDXFinder (https ://www.pdxfi nder.org/).
Magnetic resonance imaging
During image acquisition mice were kept under anesthe-
sia with 2.5% of isoflurane, with constant monitoring of 
breathing and temperature. For routine follow up, mice were 
placed in the MRI (3T MR Solutions) and a Fast Spin Echo 
T2-weighted MRI sequence was applied, with field of view 
of 25 mm, matrix size of 256 × 256, TE of 68 ms, TR of 
3000 ms, and slice thickness of 1 mm. To visualize the con-
trast enhancement, T1-weighted sequences without and with 
contrast injection were used. Fast-Spin Echo T1-weighted 
MRI was defined with the following parameters: field of 
view of 25 mm, matrix size of 256× 252, TE of 11 ms, TR 
of 1000 ms and slide thickness of 1 mm. Contrast agent 
(Gadodiamide, Omniscan, GE-Healthcare) at 0.5 mmol/kg 
was injected intravenously 1min prior to the scan. MRI data 
were analyzed by ImageJ.
Cell lines and cell line‑derived xenografts
Glioma stem-like cell (GSC) cultures (P3NS, P13NS, 
T16NS, T158NS, T226NS, T384NS, T394NS, T407NS) 
were derived from PDOXs by papain-based enzymatic 
digestion of PDOX tissue and cultured as 3D spheres in 
serum-free medium based on Neurobasal® base medium 
(Life Technologies) supplemented with 1× B27 (Life Tech-
nologies) 2 mM l-glutamine, 30 U/ml Pen–Strep, 1 U/ml 
Heparin (Sigma), 20 ng/ml bFGF (Miltenyi, 130-093-841) 
and 20 ng/ml EGF (Provitro, 1325950500). GSC NCH601, 
NCH421k, and NCH644 lines [18] were cultured as non-
adherent spheres in DMEM-F12 medium (Lonza) con-
taining 1× BIT100 (Provitro), 2 mM l-Glutamine, 30 U/
ml Pen–Strep, 1 U/ml Heparin (Sigma), 20 ng/ml bFGF 
(Miltenyi, 130-093-841), and 20 ng/ml EGF (Provitro, 
1325950500). U87 and U251 cells (obtained from ATCC, 
HTB-14) were cultured as adherent monolayers in DMEM 
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containing 10% FBS, 2 mM l-Glutamine and 100 U/ml 
Pen–Strep (all from Lonza). Cell lines were regularly tested 
for mycoplasma contamination. Cell lines were authen-
ticated by DNA profiling using an SNP-based multiplex 
approach and as compared to the other continuous cell 
lines in the DSMZ database. SNP profiles were unique. For 
in vivo experiments tumor cells (50,000–100,000 per mouse) 
were slowly injected through a Hamilton syringe (Hamilton, 
Reno, NV, USA) into the right frontal cortex. The animals 
were sacrificed upon weight loss, appearance of severe neu-
rological (locomotor problems, uncontrolled movements) or 
behavioral abnormalities (prostration, hyperactivity).
Immunohistochemistry and neuropathological 
analysis
Coronal sections from paraffin-embedded brains were 
stained with hematoxylin (Dako) and 1% eosin (H&E) 
(Sigma). For immunostaining, sections were pretreated 
for 5min with Proteinase K (Dako) followed by 30 min 
incubation at 95 °C in retrieval solution (Dako). The Dako 
Envision+System-HRP was used following the manufac-
turer’s instructions. Primary and secondary antibodies were 
incubated for 1 h. Signal was developed with 3,3′-diamin-
obenzidine chromogen in 5–20 min. Additional IHC prepa-
rations were performed using a Discovery XT automated 
staining module (Ventana) and standard protocols (list of 
antibodies in Supplementary Table 2, online resource). The 
existence of necrosis and the degree of invasion was assessed 
on the basis of H&E and human-specific Nestin staining. 
Proliferation index was determined as % Ki67-positive cells 
per whole cell population. An index of 37% was used to split 
Ki67 low and high models. IHC of mouse endothelial cells 
(CD31) was performed on isopentane flash-frozen tissues 
and cryostat sections (10 µm) were fixed with acetone and 
chloroform. Nonspecific binding was blocked with 2% FBS 
in TBS and antibodies were incubated for 1 h at RT. Pictures 
were acquired with a Leica DMI 6000B microscope. Ves-
sel quantification was done using ImageJ software. Average 
vessel area (µm2) was used as a proxy for vessel abnormality. 
Vessel area high and low models were analyzed after median 
split dichotomization into two groups. Kaplan–Meier sur-
vival analyses, including Log-rank and Wilcoxon testing 
were performed in GraphPad Prism 8. Other analyses were 
performed with two-tailed Student’s t test.
Flow cytometry
Tumor and PDOX tissue was dissociated with MACS Neural 
Tissue Dissociation Kit (P) (Miltenyi) following manufac-
turers’ instructions. For phenotyping flow experiments were 
performed as described [47]. Single cell suspensions were 
resuspended in DMEM, containing 2% FBS, 10 mM HEPES 
pH 7.4, and DNase I (10 µg/ml; Sigma) at 1 × 106 cells/ml 
followed by 90 min incubation with Hoechst 33342 (5 µg/
ml, Bisbenzimide, Ho342; Sigma) at 37 °C. After washing, 
cells were resuspended in ice-cold HBSS 2% FBS, 10 mM 
HEPES pH 7.4 buffer (100 µl/test). Prior to flow cytometric 
analysis, cells were incubated with the IR-LIVE/DEAD® 
Fixable Dead Cell Stains (Invitrogen; 1 µg/ml) and appropri-
ate preconjugated antibodies for 30 min at 4 °C in the dark 
(Supplementary Table 2, online resource). The data acquisi-
tion was performed on a FACS  AriaTM SORP cytometer (BD 
Biosciences) fitted with a 632 nm (30 mW) red laser, a 355 
(60 mW) UV laser, a 405 nm (50 mW) violet laser and a 488 
nm (100 mW) blue laser was used. The data analyses were 
done with DIVA software (BD Bioscience). For cell sorting, 
single cell suspensions were stained with the TO-PRO®-3 
shortly before sort. eGFP-negative tumor cells and eGFP-
positive mouse non-neoplastic cells were sorted to cold flow 
cytometry buffer, centrifuged, and resuspended in organoid 
culture medium. Organoids free of non-neoplastic cells were 
obtained from sorted eGFP-negative tumor cells by plat-
ing 20,000 cells per well of 24-well plates precoated with 
agar. For mixed organoids 20,000 sorted tumor cells were 
premixed with 2000 sorted eGFP-positive non-neoplastic 
mouse cells (10%). Alternative, FACS-sorted GFP-negative 
tumor cells were washed in cold HBSS buffer and processed 
directly to RNA extraction.
Ploidy assessment
Nuclei were isolated from liquid nitrogen flash frozen PDOX 
tumors [92]. Samples were minced in DAPI buffer [10 μg/
ml DAPI in 146 mM NaCl, 10 mM Tris–HCl (pH 7.5), 0.2% 
IPEGAL]. Nuclei were disaggregated subsequently with 
20G and 25G needles and filtered through a 50 μm and a 
30 μm mesh. Tumor nuclei were stained with the human-
specific anti-Lamin A/C-PE antibody (Supplementary 
Table 2, online resource). Optionally, PDOX-derived single 
cell tumor cells and cell lines were stained with IR-LIVE/
DEAD® Fixable Dead Cell Stains (Invitrogen; 1 µg/ml) and 
fixed with cold 80% ethanol. PBMCs were added to each 
sample as internal diploid control. Flow analysis was car-
ried out with  AriaTMSORP or  CantoTM flow cytometers (BD 
Biosystems). DNA content was analyzed with the FlowJo 
software.
Extraction and quality control of genomic DNA
DNA from flash frozen primary patient tissue, PDOX tumor 
tissue, PDOX-derived organoids, and GSC cultures was 
extracted using the AllPrep DNA/RNA Mini Kit® (Qiagen) 
following manufacturer’s instructions for “Simultaneous 
purification of genomic DNA and total RNA from animal 
tissues”. DNA was eluted in 50 μl of Nuclease-free water, 
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and concentrations were measured using a NanoDrop 1000 
(Thermo Fisher Scientific). Integrity of gDNA was analyzed 
with a 1% E-Gel™ EX Agarose Gel (Thermo Fisher Scien-
tific). To obtain DNA from formalin-fixed, paraffin-embed-
ded (FFPE) samples, the tissue block was punched to obtain 
a tissue core of 2 mm containing at least 70% tumor tissue. 
After a deparaffinization step (Deparaffinization solution, 
Qiagen), DNA extraction was performed using QiAamp 
DNA FFPE tissue kit (Qiagen) according to the manufac-
turer’s instruction. DNA concentrations were measured on 
the Qubit 4.0 fluorometer (Thermo Fisher Scientific), using 
the Qubit dsDNA BR Assay kit (Thermo Fisher Scientific).
Array comparative genomic hybridization 
(array‑CGH)
Array-CGHs were performed as previously described 
[92] with the following changes. DNA was fragmented 
(200–500 bp) using enzymatic digestion with RSA1 and 
Alu1 (Agilent Technologies) and labeled with the BioPrime 
array-CGH Genomic labeling Kit (Life Technologies) and 
Cy3 and Cy5 dyes (GE Healthcare) following standard pro-
tocols for Agilent array-CGH (CGH enzymatic protocol 
v6.2; Ref # G4410-90010). Female or Male gDNA pool 
(Promega) was used as a reference. All labelling reactions 
were assessed using a Nanodrop 1000 (Thermo Fisher Sci-
entific) before mixing and hybridized to either a 1 × 1 M, 
2 × 400 K, 4 × 180 K or 8 × 60 K SurePrint G3 human 
CGH microarray (Agilent Technologies) according to manu-
facturer’s instructions (CGH enzymatic protocol v6.2; Ref 
# G4410-90010). Microarray slides were scanned using an 
Agilent 2565C DNA scanner and images were analyzed with 
Agilent Feature Extraction version 12.5, using default set-
tings. The data were assessed with a series of quality control 
metrics and analyzed using an aberration detection (ADM2) 
implemented in the CytoGenomics software versions 4.2 and 
5.0.2.5 (Agilent Technologies). Aberrations were called 
using the ADM2 algorithm with a threshold setting of 6 
and an aberration filter with a minimal number of probes = 
3 and a minimal AvgAbsLogRatio = 0.25. For correlation 
analysis, each sample was initially processed with Agilent 
CytoGenomics 4.2 in order to obtain the characterization of 
genomics regions (BED files) described as one of the fol-
lowing events: “amplification”, “gain”, “loss” or “deletion. 
Next, from each file, only regions > 50 kb were extracted in 
order to construct a reference mapping file using a combina-
tion of ‘intersectBed’ and ‘multiIntersectBed’ functions from 
the BEDtools suite. Finally, BED files were mapped on that 
common reference with their corresponding type of event. 
As a consequence the resulting matrix represents features 
detectable by any of the four array types. Chromosomes X 
and Y were removed. Hierarchical clustering showed no bias 
arising from the array type used. Pearson correlation was 
applied to assess relationships between genetic profiles of 
each sample. Next, we estimated the effects of the experi-
mental factors on DNA copy number variation data. As these 
data were represented by integer values between − 2 and 
2, we were unable to fit a global linear model. Instead, we 
used a chi-squared contingency table test implemented in 
the ‘stat’ package of R. Independently for each factor and 
for each DNA site we tested, whether a distribution of copy 
numbers is different for different factor levels of the cor-
responding factor. Mean − log10(p value) and mean chi-
squared statistics were reported for graphical presentation.
Targeted DNA sequencing
500 ng of extracted gDNA were diluted in 130 μl low TE 
buffer (Qiagen) and sheared via sonication on a Biorup-
tor® UCD-200 (Diagenode) to an average fragment size of 
150–300 bp. DNA fragment size was determined using the 
DNA 1000 Kit on the Bioanalyzer 2100 (Agilent Technolo-
gies). A custom-made Agilent  SureSelectXT Target Enrich-
ment Library (Cat No. G9612B) was used for Illumina 
Paired-End Multiplexed Sequencing on a MiSeq® instru-
ment (Illumina). The panel design 1 for the Target Enrich-
ment Library was fully adapted from [85] (181 genes and 3 
promoters). Further design changes were made using Sure-
Design—Agilent eArray (Agilent Technologies) to produce 
the panel design 2, containing additional regions (234 genes 
and 3 promoters). A total of 59 samples were sequenced 22 
samples with the panel 1 and 37 samples with the panel 2. 
Library preparation was performed according to manufac-
turers’ instruction. The Illumina MiSeq® Reagent Kit v3 
(Cat No. MS-102-3003) was selected applying the Illumina 
reagent selection algorithm (https ://emea.suppo rt.illum ina.
com/downl oads/seque ncing _cover age_calcu lator .html).
Variant calling was done as follows: Raw sequencing 
reads (fastq) were quality trimmed using the tool fastp (v. 
0.20.0)[23]. Trimmed reads were aligned to an in silico 
fused reference genome (ICRG) containing the human 
genome GRCh37.75 (ENSEMBL) and the mouse genome 
mm10 using BWA mem (v. 0.7.17) [17]. Reads that mapped 
to human chromosomes were extracted from the bam file 
using SAMtools (v.1.9) and realigned to the human refer-
ence genome only [65]. Duplicates were annotated and 
removed using MarkDuplicates under GATK (v.4.0.5.1). 
Bam statistics were assessed using SAMtools and compared 
between the initial mapping to the ICRG, the realignment 
to the human genome and after removing duplicates. Single 
nucleotide variants (SNVs) and smaller insertions and/or 
deletions (indels) were called in the CLC Genomics Work-
bench (v.12.0.3) using deduplicated mappings. Variants 
were only called in regions with a minimum coverage of 
10 reads and a minimal allele frequency of 5%. All variants 
that were likely to be polymorphisms and occurred in more 
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than 1% of the gnomAD (v.2.0.2) data base were filtered out. 
SNVs were annotated with COSMIC (v.89), ClinVar, and 
dbSNP (v.150) [61]. The primary focus in SNV calling was 
to determine coding changes (missense and inframe muta-
tions), truncating (stop and frameshift mutations) and splice 
site mutations. Owing to poor coverage of TERT promoter, 
this region was excluded from the global analysis. All fil-
tered variants were manually checked to exclude artefacts 
and variants were further classified according to the Ameri-
can College of Medical Genetics and Genomics (ACMG) 
[50]. Only pathogenic, likely pathogenic or variants of 
uncertain significance (VUS) were reported. For comparing 
the %-overlap of variants between patient tissues and PDOX, 
the following thresholds were applied: minimum coverage 
10, minimum count 2, minimum frequency 5 %. Reads were 
mapped with a linear and an affine gap cost mapping and 
variants were merged after calling from both mappings.
Structural variants (SVs) and copy number alterations 
(CNAs) were analyzed using Manta (v. 1.6.0) and CNVkit 
(v.0.9.6) [24, 98]. For these analyzes alignment files with 
marked duplicates were used. SVs were annotated with 
SnpEff (v. 4.3.1t) [27] and filtered for variants with at least 
5 supporting paired and/or split reads. CNAs were called 
in two separate groups, as two versions of the sequencing 
panels were used and the target region is important for CNA 
calling via CNVkit. For panel 1 no reference samples were 
sequenced and CNA calling was performed against a flat 
reference. CNAs of all samples that were sequenced with 
the panel 2 were normalized against a reference created 
from normal samples including the commercial available 
male (Cat No. G1471) or female (Cat No. G1521) refer-
ences from Promega (Madison, Wisconsin, US) and DNA 
from blood of two patients. Segmentation was performed 
using circular binary segmentation according to default set-
tings. Gene metrics were determined for all variants with a 
minimum log2 deviation of 0.4. Workflow automation was 
performed using the workflow manager snakemake (v.5.6.0) 
under conda (v.4.7.12) [58]. Additional data handling was 
performed applying R (v.3.6) in the environment of RStudio 
(v.1.1.456). All CNAs and the SVs in EGFR were visual-
ized, manually checked, and compared to available data from 
array-CGH and array-based DNA methylation analysis.
Subclonal deconvolution via PyClone was performed 
in parallel with the above data in an independent man-
ner. PyClone input requires variants and copy number. To 
acquire these data, reads were aligned to hg38, processed 
with Picard’s MarkDuplicates {http://broad insti tute.githu 
b.io/picar d/}, and GATK indel realignment and base recali-
bration performed [105]. Variants were called using mpileup 
(Samtools v.1.9) [65] and Varscan 2’s (v.2.4.4) pileup2snp 
and mpileup2indel commands [65] with default settings but 
a p value of 1.00. Only positions in targeted regions were 
kept. Variants in dbSNP were filtered out. Absolute copy 
numbers were estimated using array-CGH. Log2 ratios were 
segmented using DNAcopy (v1.52.0) [87]. A custom script 
estimated purities and absolute copy numbers based on the 
assumption that chr7 likely had a clonal single copy gain, 
resulting in inference of one copy loss of chr10 and one 
copy gains of chr19 and chr20 (common events in GBM) 
in all analysed samples (T192, T233, T251, T158, T347, 
and T470), validating this approach. PyClone (v.0.13.1) [84] 
was run under default settings, with the addition of ‘–prior 
total_copy_number’ to indicate the use of total copy num-
bers. Purities were taken from the array-CGH estimates for 
biopsies, and was set to 1.00 for PDOX samples.
Digital PCR
Digital PCR was used to detect and quantify IDH1 R132H 
in genomic DNA using QuantStudio 3D Digital PCR Sys-
tem and IDH1 Digital PCR Mutation Detection Assays from 
Thermo Fisher (Assay ID # Hs000000036_rm for c.395G>A 
(p. R132H)) according to the manufacturer’s instructions. 
The reaction volume was 14.5 µl containing 7.5 µl QuantS-
tudio 3D Digital PCR Master Mix v2 (Thermo Fisher Scien-
tific, cat#: A26359), 0.73 µl of assay and sample DNA. Each 
assay contained forward and reverse primers, and 2 specific 
dye-labeled probes. The first one with a Vic reporter dye 
linked to the 5′end and an MGB linked to the 3′end to detect 
the WT allele. The second one with a FAM reporter dye 
at the 5′end and an MGB at the 3′end to detect the mutant 
allele. The thermal cycling conditions were 96 °C for 10 
min; 39 cycles of 60 °C for 2 min and 98 °C for 30 s; final 
extension at 60 °C for 2 min. Two replicates of each sam-
ple were run and DNA input amount was 20 ng per chip. 
Human Genomic DNA Male (Promega, cat # G1471) and 
IDH1 R132H Reference Standard (Horizon, cat # HD677) 
were used as wild type reference DNA and positive reference 
respectively. Data analysis was done with the QuantStudio 
3D Analysis Suite Cloud Software version 3.1.5; chips with 
< 15,000 partitions above the default quality threshold were 
omitted.
Array‑based DNA methylation Analysis
Methylation arrays with Infinium® MethylationEPIC were 
processed by the Helmholtz Zentrum Muenchen (Research 
Unit of Molecular Epidemiology/Institute of Epidemiology, 
German Research Center for Environmental Health, Neu-
herberg, Germany) [59] or by the Laboratoire National de 
Santé in Luxembourg. Bisulfite conversion of 250–500 ng of 
gDNA was done using the EZ DNA Methylation Kit (Zymo 
Research) according to manufacturer’s procedure, with 
the alternative incubation conditions recommended when 
using the Illumina Infinium® Methylation Assay. After 
bisulfite treatment, Infinium HD FFPE Restore kit (Illumina) 
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protocol was performed on 8 µl of DNA from FFPE sam-
ples. Genome-wide DNA methylation was assessed using 
the HumanMethylationEPIC BeadChip (Cat No. WG-317-
1001), following the Illumina Infinium® HD Methylation 
protocol. This consisted of a whole genome amplification 
step using 4 µl and 8 µl (for fresh-frozen and FFPE samples, 
respectively) of each bisulfite converted sample, followed by 
enzymatic fragmentation, and hybridization of the samples 
to BeadChips (Illumina). After a step of single-nucleotide 
extension, the BeadChips were fluorescently stained and 
scanned with Illumina HiScan SQ scanner or iScan Sys-
tem. Additional Illumina HumanMethylation450 BeadChips 
were processed according to manufacturer’s instruction at 
the German Cancer Research Center (DFKZ) Genomics and 
Proteomics Core Facility. Raw Intensity Data files (.idat) 
were exported from the BeadArray. Pearson correlation was 
applied to assess relationships between epigenetic profiles of 
each sample. The R package ‘RnBeads’ was used to gener-
ate individual 450 k and EPIC RnBeadSets [74] that were 
normalized using the ‘BMIQ’ method [100]. Both platforms 
were combined using the ‘rnb.combine.arrays’ function in 
order to extract only common sites present in both objects 
with corresponding DNA methylation level. The DNA meth-
ylation level for each locus was measured as a beta-value 
score; that can range from zero to one with scores of zero 
indicating completely unmethylated DNA and scores of one 
indicating complete methylated DNA. Hierarchical cluster-
ing showed no bias arising from the array type used. Pearson 
correlation and Principal component analysis (PCA) were 
applied to assess relationships between epigenetic profiles 
of each sample.
As several of the considered factors were strongly cor-
related, we estimated their importance by consequent fitting 
unavailable ANOVA models, independently for each CpG 
site and factor. Mean F statistics over all variable CpG cites 
was then used to illustrate the importance of the factors. To 
detect differentially methylated regions (DMRs) or CpGs 
(DMCs), IDAT files were subjected to background correc-
tion, global dye-bias normalization, calculation of DNA 
methylation level, and detection p values using ‘methylumi.
noob’ within the ‘RnBeads’ package. Differential methyla-
tion analysis was conducted on genomic site and region level 
according to sample groups (Patient vs. PDOX or IDHwt 
vs. IDH1mut) using ‘limma’ and fitted using an empirical 
Bayes approach on M values [90]. In general, array probes 
were divided into 4 different genomic regions, giving info 
on functional genomic distribution: (1) tiling regions with a 
window size of 5kb distributed over the whole genome, (2) 
genes and (3) promoters annotated with Ensembl gene defi-
nitions from the biomaRt package. Promoters were defined 
as the region spanning 1500 bases upstream and 500 bases 
downstream of the TSS of the corresponding gene. (4) CpG 
islands tracked from UCSC genome browser. Furthermore, 
probes were divided into those within CpG islands (CGI), 
in CGI shores, shelves, or open seas (with or without over-
lapping gene bodies). In the comparison between ‘Patient’ 
and ‘PDOX’, the following criteria were selected: adj. p 
value < 0.01, absolute difference in mean methylation β 
value > 0.2. Beta value distribution plots for probe catego-
ries (‘Open Sea’, ‘Shelf’, ‘Shore’ or ‘Island’) were extracted 
from the integrated ‘Exploratory Module’ from ‘RnBeads’. 
Global beta value density plots for longitudinal samples 
were generated using the ‘minfi’ package in R, after Noob 
background correction and global dye-bias normalization. 
The analysis of CpG methylation signatures was performed 
as described previously [33], where DNA methylation pro-
files were compared to a large cohort of the patient glioma 
tumors. DNA methylation-based glioma classification was 
performed by referencing data to the dataset of over 2800 
neuropathological tumors at https ://www.molec ularn europ 
athol ogy.org/mnp as described previously [20] .
Genome‑wide gene expression analysis
Total RNA was extracted using the QIAGEN® RNeasy 
Mini Kit according to the manufacturer’s protocol. Gene-
Chip® Human Gene 1.0ST Arrays were used to deter-
mine the expression profiles. Total RNAs were processed 
using the Ambion WT expression kit (Life Techniologies) 
and the Affymetrix WT Terminal & Labeling kit before 
being hybridized on Affymetrix arrays according to the 
manufacturer’s instructions (protocol P/N 702808 Rev.6). 
Upon hybridization, microarrays were washed, stained, 
and scanned according to manufacturer’s standard proce-
dures. Affymetrix CEL files containing hybridization raw 
signal intensities were processed to gene expression signals 
using the RMA (robust multichip average) algorithm imple-
mented in the oligo package (version 1.44.0). hugene10st-
transcriptcluster.db package version 8.7.0 was then used to 
map Affymetrix ID to entrez gene ID. R statistical environ-
ment was used for hierarchical clustering, principal compo-
nent analysis and for empirical Bayesian statistics (LIMMA 
[90], R/Bioconductor). List of differentially expressed genes 
(DEG) were obtained with the eBayes/LIMMA. FDR was 
calculated with the Benjamini and Hochberg approach [8]. 
Thresholds were set up for FDR < 0.01 and absolute fold 
change (abs(FC)) ≥ 2. The Metascape® database [118] was 
used for data mining.
The similarity between our patient biopsies, PDOXs and 
cell lines with GBM tumors from The Cancer Genome Atlas 
(TCGA) cohort (538 GBM samples) was investigated using 
gene expression data [19]. Our cohort’s data were ranked 
based on their interquartile ranges to select the top-5000 
(most variable) probes across samples. We focused on 
probes with mapped gene symbols, for genes with multiple 
probes their expression values were (mean) merged with 
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Babelomics 5 [3]. Filtering resulted in 4069 unique gene 
symbols. TCGA data were downloaded from The Broad 
Institute GDAC Firehose (http://gdac.broad insti tute.org), 
and the preprocessed gene expression data (RSEM values) 
were analyzed. Gene symbols from our cohort were matched 
to the TCGA data, and 2420 unique symbols were unam-
biguously found in both datasets. Using the expression data 
for these genes, we measured (Spearman) correlation coef-
ficients between our cohort samples and TCGA tumors. The 
resulting correlations with the TCGA tumors were ranked 
and graphically visualized in terms of individual samples 
and sample groups. Analyses were implemented with the R 
statistical language, packages corrplot, and ggplot2 (https ://
www.r-proje ct.org).
Consensus independent component analysis (ICA), a 
data-driven dimensionality reduction method that performs 
a matrix decomposition, was applied to assess signals arising 
from nonmalignant cells. ICA with k components represents 
log2-transformed gene expression matrix X as a matrix prod-
uct of matrices S (signals) and M (weights). The first shows 
contribution of genes in k statistically independent signals. 
Biological meaning of these signals was detected by func-
tional annotation of the most contributing genes. In order to 
improve reproducibility of ICA decomposition, which can 
be affected by the selection of initial estimations, we applied 
consensus ICA approach [76]. ICA was run multiple times 
and the resulted matrices S and M were mapped and aver-
aged between the runs. The analysis of the cell lines and 
TCGA reference dataset was performed as described in [76].
Single cell RNA‑Seq using Drop‑Seq
For scRNA-seq experiments PDOXs derived in nude mice 
were used. To obtain a pure population of single viable cells 
and to distinguish human tumor cells from mouse TME sub-
populations PDOXs were dissociated and FACS-sorted (P3, 
P8, P13) or MACS-purified (T16, P13). For FACS we have 
separated hCD90 positive tumor cells from hCD90 negative 
mouse TME subpopulations [36]. MACS-based purification 
was performed with Myelin Removal Beads II followed by 
Mouse Cell Depletion kit (Miltenyi Biotec) according to 
manufacturer’s protocols. Prior to cell loading on the Drop-
seq chips, the viability of cells was verified and concentra-
tion was adjusted to ~ 150 cells/μl as optimal concentration 
to achieve single cell encapsulation within each droplet of 
~ 1 nl. All samples analyzed had a cell viability > 95%.
Microfluidics devices were fabricated using a previously 
published design [70]. Soft lithography was performed using 
SU-8 2050 photoresist (MicroChem) on 4” silicon substrate 
to obtain a feature aspect depth of 100 μm. After overnight 
silanization (using Chlorotrimethylsilane, Sigma), the wafer 
masks were used for microfluidics fabrication. Drop-seq 
chips were fabricated using silicon based polymerization 
chemistry. Briefly, Polydimethylsiloxane (PDMS) base 
and crosslinker (Dow Corning), were mixed at a 10:1 ratio, 
mixed and degassed before pouring onto the Drop-seq mas-
ter template. PDMS was cured on the master template, at 
80 °C for 2 h. After incubation and cooling, PDMS slabs 
were cut and the inlet/outlet ports were punched with 1.25 
mm biopsy punchers (World Precision Instruments). The 
PDMS monolith was plasma-bonded to a clean micro-
scopic glass slide using a Harrick plasma cleaner. Immedi-
ately after pairing the plasma-treated surfaces of the PDMS 
monolith and the glass slide, flow channels of the Drop-seq 
chip were subjected to a hydrophobicity treatment using 
1H,1H,2H,2H-Perfluorodecyltrichlorosilane (in 2% v/v in 
FC-40 oil; Alfa Aeser/Sigma). After 5 min of treatment, 
excessive silane was blown through the inlet/outlet ports. 
Chips were further incubated at 80 °C for 15 min.
Experiments followed the original Drop-seq protocol 
[70] with minor changes. Synthesized barcoded beads 
(Chemgenes corp., USA) were co-encapsulated with cells 
inside the droplets containing lysis reagents using an opti-
mal bead concentration of 200 beads μl−1 in Drop-seq Lysis 
buffer medium. Cellular mRNA was captured on the beads 
via barcoded oligo (dT) handles synthesized on the surface. 
For cell encapsulation, 2 ml of cell and bead suspensions 
were loaded into 3 ml syringes (BD), respectively. To keep 
beads in homogenous suspension a microstirrer was used 
(VP scientific). The QX 200 carrier oil (Bio-rad) used as 
continuous phase in the droplet generation was loaded into 
a 20 ml syringe (BD). For droplet generation, 3.6 ml per h 
and 13 ml per h were used in KD scientific Legato syringe 
pumps for the dispersed and continuous phase flows, respec-
tively. After stabilization of droplet formation, the droplet 
suspension was collected into a 50 ml Falcon tube. Col-
lection of the emulsion was carried out until 1 µl of the 
single cell suspension was dispensed. Droplet consistency 
and stability were evaluated by bright-field microscopy 
using INCYTO C-Chip Disposable Hemacytometer (Fisher 
Scientific). Bead occupancy within droplets was carefully 
monitored to avoid multiple bead occupancy. The subse-
quent steps of droplet breakage, bead harvesting, reverse 
transcription, and exonuclease treatment were carried out 
in accordance to [70]. RT buffer contained 1× Maxima RT 
buffer, 4 % Ficoll PM-400 (Sigma), 1 μM dNTPs (Ther-
moScientific), 1 U/ml Rnase Inhibitor (Lucigen), 2.5 μM 
Template Switch Oligo, and 10 U/ml Maxima H-RT (Ther-
moScientific). Post Exo-I treatment, the bead counts were 
estimated using INCYTO C-Chip Disposable Hemacytom-
eter, and 10,000 beads were aliquoted in 0.2 ml Eppendorf 
PCR tubes. PCR mix was dispensed in a volume of 50 μl 
using 1× Hifi HotStart Readymix (Kapa Biosystems) and 
0.8 mM Template-Switch-PCR primer. The thermocycling 
program for the PCR amplification was modified for the final 
PCR cycles by 95 °C (3 min), four cycles of 98 °C (20 s), 
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65 °C (45 s), 72 °C (3 min), 10 cycles of 98 °C (20 s), 67 °C 
(20 s), 72 °C (3 min) and followed by a final extension step 
of 72 °C for 5 min. Post PCR amplification, libraries were 
purified with 0.6× Agencourt AMPure XP beads (Beckman 
Coulter), in accordance with the manufacturer’s protocol. 
Finally, the purified libraries were eluted in 20 μl RNAse/
DNAse-free molecular grade water. Quality and concentra-
tion of the sequencing libraries were assessed using BioAna-
lyzer High Sensitivity Chip (Agilent Technologies).
The 3′end enriched cDNA libraries were prepared by 
tagmentation reaction of 600 pg cDNA library using the 
standard Nextera XT tagmentation kit (Illumina). Reactions 
were performed according to the manufacturer’s instruc-
tions, samples were barcoded using the N7xx index series 
and 400 nM custom P5 hybrid primer: (AAT GAT ACG GCG 
ACC ACC GAG ATC TAC ACG CCT GTC CGC GGA AGC AGT 
GGT ATC AAC GCA GAG T*A*C). The PCR amplification 
cycling program used was: 95 °C 30 s; fourteen cycles of: 
95 °C (10 s), 55 °C (30 s), 72 °C (30 s) followed by a final 
extension step of 72 °C (5 min). Libraries were purified 
twice to reduce primers and short-DNA fragments with 0.6× 
and 1× Agencourt AMPure XP beads (Beckman Coulter), 
respectively, in accordance with the manufacturer’s proto-
col. Finally, purified libraries were eluted in 15 μl molecular 
grade water. Quality and quantity of the tagmented cDNA 
library was evaluated using BioAnalyzer High Sensitivity 
DNA Chip. The average size of the tagmented libraries prior 
to sequencing was between 400 and 700 bps. Purified Drop-
seq cDNA libraries were sequenced using Illumina NextSeq 
500 with the recommended sequencing protocol except for 
6pM of custom primer (GCC TGT CCG CGG AAG CAG TGG 
TAT CAA CGC AGA GTA C) applied for priming of read 1. 
Paired end sequencing was performed with the read 1 of 
20 bases (covering the random cell barcode 1–12 bases and 
the rest 13–20 bases of random unique molecular identifier 
(UMI) and for read 2 the 50 bases of the genes.
Bioinformatic processing followed the DropSeq pro-
tocol [70] using the DropSeq tool version 1.16. In brief, 
FASTQ files were assembled from the raw BCL files 
using Illumina’s bcl2fastq converter and ran through the 
FASTQC codes [Babraham bioinformatics; https ://www.
bioin forma tics.babra ham.ac.uk/proje cts/fastq c/] to check 
library qualities by the assessment parameters (a) quality 
per base sequence, (b) per base N content, (c) per base 
sequence content and d) over-represented sequences. 
Libraries with significant deviation were re-sequenced. 
FASTQ files were subsequently merged and converted 
to binaries using PICARD’s fastqtosam algorithm. The 
resulting digital gene expression matrix (DGE) was first 
cut based on knee plot analysis and subsequently filtered 
by the Seurat version 3 and Monocle version 2 packages 
(http://cole-trapn ell-lab.githu b.io/monoc le-relea se/) in 
R (version 3.6.0) based on ribosomal and mitochondrial 
genes as well as on low transcript content. The following 
threshold filters were used: only cells that expressed at 
least 200 genes and presented  1x106 total mRNAs, and 
only genes which were expressed in at least 5 cells were 
considered for further analysis. To normalize for transcript 
capturing between the beads, the averaged normalized 
expression levels (log2(TPM+1)) were calculated. After 
filtering and normalization, our dataset included 3138 cells 
(per sample cell counts: P3 = 543 cells, P8 = 502 cells, 
P13 = 1295, T16 = 798 cells). To examine relative expres-
sion levels, we centered the data by subtracting the aver-
age expression of each gene from all cells. Digital gene 
expression matrix of the TME subpopulations of PDOX 
P8 and normal mouse brain was filtered and normalized 
as described above. After filtering and normalization, the 
dataset included 892 cells (per sample cell counts: P8 = 
453 cells, Control = 439 cells). Dimensionality reduction 
and gene expression markers identification and visualiza-
tion were done using UMAP implemented in the Seurat 
package version 3 [15, 93].
The cell cycle and hypoxia meta-signatures were deter-
mined based on the respective Molecular Signatures Data-
base (MsigDB [95]) and only correlated genes (R > 0.3) 
were considered. The relative expression of common 
signature genes between all samples was depicted in the 
expression heatmaps. For each cell cycle and hypoxia sig-
nature, a specific meta-module was defined, taking into 
account all genes that were common among the samples, 
and the average relative expression for each specific meta-
module was calculated. These meta-modules were used 
to score the cells by the average relative expression of all 
genes in the meta-module, and cells were sorted according 
to these scores. The global score for each sample was cal-
culated as the average of all cell cycle and hypoxia meta-
modules expression. Meta-modules were also defined for 
the G1/S and G2/M phases of the cell cycle, which ena-
bled cells to be classified as cycling (mean relative expres-
sion ≥ 0.1 and qval < 0.05) and noncycling (mean rela-
tive expression < 0.1 and qval > 0.05). For each cell, the 
mean relative expression of unique tumor subtype genes 
was calculated and used to create a score for each respec-
tive subtype. The minimum and maximum score values 
were determined and only cell scores above the threshold 
(qval > 0.001) were used to generate the tumor subtype 
heatmaps. Single cell signature scores for cellular phe-
notypic states and meta-modules (MES, AC, NPC, and 
OPC-like) were implemented as described by Neftel et al. 
[77]. TCGA subtypes of single cells were assessed based 
on signatures described in Wang et al. [112]. Owing to 
the limitations of Drop-seq data, the signature scores for 
TCGA subtypes were determined according to scripts from 
Neftel et al. [77].
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Western blot
Protein extraction was performed using minimal amounts 
of RIPA buffer (Thermo Fisher Scientific, Cat No. 89901) 
containing 1x protease inhibitor (Merck,  cOmplete® protease 
inhibitor cocktail) and on ice incubation for 15min followed 
by brief sonication and a centrifugation step (13.000 ×g, 
5 min, 4 °C) to remove cellular debris. iProtein extracts were 
resolved in  NuPageTM 4–12% BisTris Protein Gels (Cat No. 
NP0321BOX, Thermo Fisher Scientific, MA, US), and blot-
ted onto an  InvitrolonTM PVDF (Thermo Fisher Scientific, 
Cat No. LC2005) or a Nitrocellulose membrane (Lifetech, 
Cat No. IB23001) according to standard protocols. After 
incubation with 5% nonfat milk in TBST (10 mM Tris, pH 
8.0, 150 mM NaCl, 0.5% Tween 20) for 60 min, the mem-
brane was rinsed with TBST and incubated with primary 
antibodies (Supplementary Table 2, online resource). Mem-
branes were washed three times for 10 min and incubated 
with horseradish peroxidase (HRP)-coupled secondary anti-
bodies (Jackson ImmunoResearch) for 1h at RT. Blots were 
washed with TBST three times, once with TBS, developed 
with a chemiluminescent substrate (ThermoFisher) and 
imaged with the ImageQuant 350 scanning system (cooled-
CCD camera, GE Healthcare).
Ex vivo compound screening in 384‑well plate 
format
PDOX tumors were dissociated with the MACS Neural 
Dissociation kit (Miltenyi Biotec) according to manufac-
turer’s instructions. Mouse cells were removed with Mouse 
Cell Depletion kit (Miltenyi Biotec). Tumor cells were 
seeded 1000 cells/well in organoid medium in 384-well 
plates (PrimeSurface®, S-Bio) and cultured for 72 h to 
allow organoid formation. Organoids were treated with the 
following compounds: Erlotinib (EGFR, SelleckChem), 
Gefitinib (EGFR, SelleckChem), AZD3759 (EGFR, 
SelleckChem), AG-490 (JAK2, EGFR, SelleckChem), 
Daphnetin (EGFR, PKA/C, SelleckChem), Palbociclib 
(CDK4/6, SelleckChem), Abemaciclib (CDK4/6, Sell-
eckChem), TMZ (Sigma) and 1,2:5,6-Dianhydrogalactitol 
(VAL-083, Delmar) in a fourfold and seven-point serial 
dilution series ranging from 1 µM to 1 mM (VAL-083, 
TMZ) or 12 nM to 48 μM (remaining inhibitors). After 
3 (TMZ, VAL-083) or 6 (remaining inhibitors) days of 
incubation at 37 °C in a 5%  CO2 humidified incubator for 
respective inhibitors, cell viability and cytotoxicity were 
measured with CellTiter-Glo®2.0 and  CellToxTM-Green 
assays (Promega) respectively according to the manufac-
turer’s instructions with a ClarioStar plate reader (BMG 
Labtech). The relative cell viability for each dose was 
obtained by normalization with untreated control (VAL-
083) or dimethyl sulfoxide (DMSO, Sigma, remaining 
compounds) per each plate or condition. Dose response 
curves (DRCs) were fitted using GraphPad Prism 8: best-
fit lines and the resulting  IC50 values were calculated using 
log[inhibitor] versus normalized response—variable slope 
(four parameters). The area under the curve (AUC) for 
each DRC was calculated using GraphPad Prism 8. The 
experiments were performed with one (VAL-083, TMZ) 
or two (EGFR and CDK4/6 inhibitors) biological rep-
licates, each comprising three technical replicates per 
PDOX model per each drug concentration. Statistical dif-
ferences between genetically defined PDOXs groups were 
performed with unpaired 2-tailed t test. For LIVE/DEAD 
double labeling, organoids were incubated with 2 mM 
Calcein-AM and 4 mM Ethidium homodimer-1 (LIVE/
DEAD assay kit, Molecular Probes) for up to 6 h. Imag-
ing of viable (green) and dead (red) cells was done using 
LSM510 or LSM880 Confocal Laser microscopes (Zeiss).
Cell printing and high‑throughput drug screening 
procedure
PDOX T434 tumors were dissociated with the MACS Neu-
ral Dissociation kit (Miltenyi Biotec) according to manu-
facturer’s instructions. Mouse cells were removed with 
Mouse Cell Depletion kit (Miltenyi Biotec). Tumor cells 
were mixed with 1% alginate (ratio of 1:1) and printed on 
384-pillar array (1000 cells with 250 nl) by ASFA Spotter 
ST (Medical & Bio Device, Suwon-si, South Korea). The 
pillars were washed by carefully combining the cell-pillar 
plates with 384-well plates containing 40 µl of cell culture 
medium (DMEM (Biowest), 10% FBS, 1% Pen–Strep, 4x 
NEAA (Lonza), 1% Ultraglutamine (Lonza)) in each well, 
and incubation for 30 min at 37 °C. The pillar plates were 
then combined with 384-well assay plates containing cell 
culture medium and incubated for 3 days at 37 °C and 5% 
 CO2 atmosphere. The pillar plates were then transferred 
to compound plates where the cells immobilized in algi-
nate were exposed for 7 days to 41 FDA-approved drugs, 
in a fourfold and seven-point serial dilution series from 
7.3 nM to 30 μM in duplicates. Bortezomib was used as 
an internal control. To determine end-point cell viability, 
the cells were stained using Calcein AM live cell staining 
and the images were acquired using High Content imaging 
instrument (CV8000, (Yokogawa, Tokyo, Japan). Cell via-
bility was calculated based on Calcein AM fluorescence. 
The relative cell viability for each dose was obtained by 
normalization with dimethyl sulfoxide (DMSO) per each 
plate. The experiment was performed in two replicates on 
different 384 well plates. Dose Response Curves (DRC) 
were fitted using GraphPad Prism 8 (GraphPad). The AUC 
for each DRC was calculated using GraphPad Prism 8.
929Acta Neuropathologica (2020) 140:919–949 
1 3
In vivo tumor treatment
T16 GBM organoids were orthotopically implanted into the 
right frontal lobe of Swiss nude mice. Animals were moni-
tored daily and the following criteria were evaluated: (1) 
loss of > 10% of body weight, (2) exhibition of strong neu-
rological signs (3) increased kyphosis or (4) swollen belly. 
Tumor growth was monitored by MRI (T1- and T2-weighted 
MRI protocol; 3T MRI system, MR Solutions). 35 days post-
implantation most mice had visible tumors and were rand-
omized into 4 treatment groups (7 mice per treatment group, 
6 mice per control group): Control, Bevacizumab (Avastin) 
treatment, VAL-083 treatment and combined Bevacizumab 
+ VAL-083 treatment. Drug concentrations and treatment 
schedule were as follows: Bevacizumab – 20 mg/kg, 1× 
week, VAL-083 − 3.5 mg/kg, 3× week. Control animals 
received saline (NaCl 0.9%) 4× week. Compounds and 
saline were delivered by intraperitoneal injections. Beva-
cizumab and VAL-083 injections were performed on dif-
ferent days. 49 days after implantation MRI T2 was applied 
to monitor tumor progression. T1 with contrast agent was 
applied to several mice to evaluate the response of tumor to 
Bevacizumab. 56 days after implantation one mouse in con-
trol group showed neurological symptoms and was eutha-
nized directly after MRI. T2 and T1 + contrast MRI was 
applied to all mice. Remaining mice were euthanized the 
following day before mice developed symptoms and brains 
extracted. Tumor volume  (mm3) was measured in ImageJ as 
the sum of area obtained by tumor delineation in each slice 
and multiplying by slice thickness (1mm). Growth rate (GR) 
was calculated using the TV measurement as GR = 100 × 
log (TVf/TV0)/(tf−t0), where TVf and TV0 are the tumor 
volumes at the late (day 56) and early (day 35 or day 49) 
time points, respectively, and tf−t0 is the difference in days 
between the time points. Tumor volumes are expressed in 
 mm3 and GR in % per day [80]. Statistical difference was 
assessed with ANOVA with Turkey’s multiple comparison 
test.
Statistical tests
Different statistical approaches have been applied based 
on the data type and measurements across the manuscript. 
Statistical tests are described in each paragraph above cor-
responding to the associated experimental procedures. If not 
specified above, significant differences were calculated with 
the Student’s t test.
Data availability
Our PDOX models are freely available to the scientific 
community. To facilitate the access to established models, 
we provide detailed information for the best characterized 
models via PDXFinder (https ://www.pdxfi nder.org/) [30]. 
New models will be regularly added to the resource with 
molecular and histopathological characterization. Our col-
lection is also part of the EuroPDX consortium (https ://
www.europ dx.eu/). Models are available from the corre-
sponding author on reasonable request. The sharing proce-
dure will depend on the expertise of the requesting labora-
tory. Groups experienced in organoid culture and intracranial 
implantation will be provided with the organoids. For less 
experienced groups we provide additional training or per-
form collaborative experiments in house. For small scale 
experiments we provide ready-to-use material, e.g., tissue 
sections, cryopreserved organoids, or single cells.’
Molecular data are available in the Gene Expression 
Omnibus repository (https ://www.ncbi.nlm.nih.gov/geo/) 
under accession numbers as follows: (1) array-CGH: 
GSE137959; (2) DNA methylation: GSE137845; (30 gene 
expression: GSE134470; (4) scRNA-seq:GSE128195. Tar-
geted DNA sequencing is available in the Sequence Read 
Archive (https ://www.ncbi.nlm.nih.gov/sra) under accession 
number PRJNA627814.
Results
Glioma organoids and PDOXs can be generated 
across diverse clinical high‑grade glioma specimens
Fresh tumor samples of 241 glioma patients (189 GBM, 52 
grades II-III gliomas) were collected at surgery, including 
from multifocal samples and longitudinal samples of patients 
undergoing sequential operations (Fig. 1a, b, Supplemen-
tary Table 1, online resource). Organoids of 300–1000 µm 
were obtained by mechanical dissociation of tissue, with-
out enzymatic digestion, followed by self-aggregation in 
short-term culture (up to 14 days). These cultures represent 
self-organizing structures, which preserve a heterogeneous 
3D tumor tissue organization, including cell–cell interac-
tions, non-neoplastic cells of the tumor microenvironment 
(TME) and extracellular matrix components. The initial 
culture step allows to shed necrotic cells and to standard-
ize the organoids for intracranial implantations. Sufficient 
material was available for cultures from 72% (136 GBM, 
37 grades II–III gliomas, total 173) of collected patient 
samples, of which 79% GBMs (107/136) and 68% (25/37) 
of grades II–III gliomas presented high quality organoids. 
Common reasons for lack of healthy organoids were 
necrotic tissue, tissue damage during surgical procedure or 
insufficient material. In general, organoids self-assembled 
into 3D structures within 3–5 days. The proliferation and 
growth of organoids was generally limited, but variable 
and patient specific. We used patient-derived organoids for 
downstream applications within 10–14 days of short-term 
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culture. Occasionally we mechanically recut larger organoids 
to ensure good quality and avoid necrosis. Although orga-
noids can remain viable in culture over longer periods, they 
often fuse to re-aggregate into larger structures. We have not 
attempted further expansion and passaging in order to limit 
in vitro selection processes. Organoids were either frozen 
in DMSO-containing medium for later recovery or directly 
implanted into the rodent brain. No enzymatic or mechanical 
dissociation of organoids was applied prior implantation or 
cryopreservation.
To date, out of the 173 generated glioma organoids, we 
have performed 49 implantations into the mouse brain (41 
GBM and 8 grade III gliomas). Organoids were implanted 
in immunodeficient mice (NOD/Scid, NSG) and tumors 
developed within 4–57 weeks depending on the parental 
tumor (Generation 1). The developed tumors were further 
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resected from the mouse brain and organoids (Generation 
1) were obtained by applying the same protocol as for 
patient tumor tissue. IDHwt GBM organoids survived well 
a freezing–defrosting procedure, while IDH1mut (R132H) 
gliomas were more fragile, often requiring implantation 
of freshly prepared organoids or small unprocessed tis-
sue fragments. Generally, mice showed a longer latency 
period at first passage (Supplementary Fig. 1a, online 
resource) and the most PDOXs reached a stable tumor 
development time per patient tumor at Generation 2–4. 
Successful engraftment and PDOX propagation via serial 
transplantation (> 3 passages) were obtained for 86% 
of GBMs (35/41, 6 failed due to poor organoid quality), 
25% of grade III gliomas (2/8, no association with orga-
noid quality). Grade II gliomas were not systematically 
implanted because of minimal prior success. Rare acti-
vating IDH2mut (R172K) gliomas are not yet present in 
the cohort. Three additional GBMs (PDOXs P3, P8, and 
P13) were initially derived in nude rats [111] and were 
further serially transplanted in mice. To date, we have 
generated a cohort of 40 glioma PDOX models from 32 
patients, displaying different clinical characteristics and 
molecular backgrounds (Fig. 1b, Supplementary Table 1, 
online resource). Our PDOX cohort contains tumors from 
primary untreated gliomas as well as recurrent tumors 
after treatment. We obtained paired longitudinal samples, 
before and after treatment, from 7 patients and were able to 
generate 15 corresponding PDOXs. One patient (LIH0831) 
with a multifocal GBM led to 2 PDOX models derived 
from tumor tissue collected from two distinct locations. 
Out of 25 PDOX models cultured in serum free medium 
in vitro, 8 glioma stem cell-like (GSC) lines could be 
propagated long term, including 2 cell lines carrying the 
IDH mutation (Supplementary Table 1, online resource).
Glioma PDOXs display a range of invasive 
and angiogenic glioma features
PDOXs derived in immunodeficient mice preserved the 
major histopathological features of patient tumors and dis-
played a gradient of invasiveness and vascular pathology 
depending on the tumor of origin (Fig. 1c). Angiogenic 
tumors tended to grow in a more circumscribed manner 
and showed contrast enhancement on MRI, indicative of 
blood brain barrier disruption. In line with our previous 
report [12], mouse survival was a result of a combination of 
histopathological features (vascular proliferation, necrosis, 
and invasion) and proliferation index, where high prolifera-
tion correlated significantly with poor prognosis (Fig. 1d, e, 
Supplementary Table 1, online resource). Models derived 
from relapsed GBMs showed similar survival and prolifera-
tion index as compared to treatment-naïve tumors (Supple-
mentary Fig. 1b, c, online resource). Based on the previous 
experiments with GBM PDOXs generated in rats [111], 
we were surprised to find that only a few PDOX models 
in mice displayed extensive abnormalities in blood vessels. 
Therefore, we compared identical patient GBMs implanted 
in either mouse or rat brain. While invasive tumors were 
similar in mice and in rats, vessel abnormalities were exac-
erbated in rats in the PDOXs showing only moderate defects 
in the mouse brain (Fig. 1f, Supplementary Fig. 1d, online 
resource), including pseudopalisading necrosis, dilated ves-
sels, and endothelial cell proliferation. This indicates that the 
capacity of human GBM to induce angiogenesis is higher 
in rats as compared to mice, likely due to differences in size 
and cross-species interactions. These interspecies differences 
were also observed in xenografts derived from serum-free 
GSC lines (Supplementary Fig. 1d, online resource).
Tumor development was independent 
of non‑neoplastic cells present in organoids
Non-neoplastic cells of the TME constituted between 3 and 
25% of all cells in tumor cores in different PDOX models 
(Supplementary Fig. 1e, online resource) and these propor-
tions remained stable over serial transplantations. To assess 
whether the nontumor compartment present within orga-
noids influenced tumor formation upon implantation in vivo, 
we derived TME-free organoids from FACS-purified tumor 
cells grown in eGFP-expressing mice and compared them 
with TME-containing organoids (Supplementary Fig. 1f–g, 
online resource). Both conditions allowed for reformation 
Fig. 1  Clinical and histological characterization of the glioma PDOX 
cohort. a Schematic of derivation of PDOXs from primary and recur-
rent patient gliomas. Treatment refers to patients. PDOXs enable 
tumor expansion via serial transplantation, organoid-based in  vitro 
assays including drug screening, genetic manipulations, and deriva-
tion of long-term in vitro sphere cultures. b Clinical patient informa-
tion of corresponding 40 PDOXs (from 32 patients). PDOXs derived 
from longitudinal or multifocal samples of the same patients are 
highlighted. See Supplementary Table  1, online resource for more 
information. c MRI, Hematoxylin/Eosin, human-specific Nestin, 
and mouse-specific CD31 stainings were performed to assess histo-
pathological characteristics of PDOXs. Representative PDOX mod-
els displaying a range of invasive and angiogenic features are shown. 
Scale bars represent 1mm (black) and 100µm (white). d Kaplan–
Meier survival curves of PDOXs divided in high and low Ki67 posi-
tive cells (mean Ki67 positive cells per model - split by median), 
***pvalue < 0.001 (Wilcoxon signed-rank test). Mean survival of each 
model ≥ generation 3 was plotted in each group. e Kaplan–Meier sur-
vival curves of PDOXs divided by vessel area (Average vessel area in 
µm—split by median value), ns = not significant (Wilcoxon signed-
rank test). Mean survival of each model ≥ generation 3 was plotted 
in each group. f Histopathological comparison of the same PDOXs 
derived in mice or rats. Angiogenic features are amplified in the rat 
brain (arrows, abnormal vessel morphology; stars, pseudopalisading 
necrosis; black bar, 1 mm; white bar, 100 µm). Examples are shown 
for pronounced invasive histopathology (P8), intermediate (T16) and 
increased angiogenic (P13) growth. Scale bars represent 1 mm. See 
more examples in Supplementary Fig. 1d, online resource 
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of 3D organoid structures from sorted cells. Comparison of 
tumors derived from these two types of organoids showed 
no significant difference in survival over serial transplan-
tations (Supplementary Fig.  1g, online resource). The 
resulting tumors appeared histologically similar, with the 
expected level of invasion and the presence of an abnormal 
vasculature. This shows that tumors quickly adapt to the new 
microenvironment and recreate their niche in the brain by 
recruiting host-derived TME at each passage.
Copy number alterations (CNAs) are well preserved 
in glioma PDOXs
Glial tumors display considerable genetic heterogeneity, 
with both inter- and intratumoral differences [91]. At the 
DNA ploidy level, we have previously shown that GBMs 
present as either mono- or polygenomic tumors where ane-
uploidy represents a late event in GBM evolution [92]. We 
found that the PDOXs retain the patient tumor ploidy states 
and that both pseudodiploid and aneuploid clones could be 
propagated by serial implantation (Supplementary Table 1, 
online resource). This is in contrast to long term cultures, 
where GSC lines of pseudodiploid tumors undergo addi-
tional aneuploidization at early passages (Supplementary 
Fig. 2a, online resource). By array-CGH, we show that at 
scale CNAs of the parental tumors were maintained with 
high fidelity in organoids and PDOXs both at low and high 
generations (Fig. 2a, Supplementary Fig. 2b, c, Supplemen-
tary Table 3, online resource). PDOXs clustered next to or 
in close proximity to their parental tumors. This was also 
true for longitudinal gliomas, where similar genomic pro-
files were seen in recurrent tumors after treatment (Fig. 2b, 
Supplementary Fig. 2d, online resource). Genomic aberra-
tions were also assessed and confirmed by DNA Infinium 
Methylation EPIC arrays (Supplementary Table 3, online 
resource). Most GBM patients harbored classical genetic 
hallmarks, such as chromosome 7 gain, chromosome 10 loss 
and CDKN2A/B deletion, which were all retained in PDOXs. 
This is in contrast to subcutaneous PDXs, where classical 
GBM CNAs where reported to be lost [7]. Moreover, focal 
amplicons (e.g., EGFR, MDM2, MDM4, PDGFRA, MET, 
CDK4/6) with the exact same breakpoints were maintained 
in PDOXs over generations (Fig. 2c, Supplementary Fig. 2c, 
online resource). IDH1mut gliomas, of which PDOXs could 
be established, displayed a remarkable genomic complexity 
(Fig. 2d, Supplementary Tables 1, 3, online resource).
Rare genetic discrepancies reflect intratumor 
heterogeneity and tumor‑specific evolution
It has been suggested that tumors may undergo mouse-
specific tumor evolution in subcutaneous PDXs [7]. Here, 
in our orthotopic xenografts, we only detected minor dif-
ferences between PDOXs and patients, which could largely 
be explained by clonal heterogeneity of the parental tumor, 
particularly at the level of focal amplifications known to be 
subclonal [45]. E.g., patient tumor T16 displayed intratumor 
genetic heterogeneity, where differences in gene amplicons 
for EGFR and MDM2 were detected in different tissue frag-
ments dissected from the tumor core (Fig. 2e). Yet another 
fragment carrying MDM4 and EGFR amplification with 
Δ25−27 structural variant generated the initial 3D orga-
noids and was further propagated in vivo over subsequent 
passages. This was similar for PDOXs T341, P8 and T158 
(Supplementary Fig. 2e, g, Supplementary Table 3, online 
resource). These changes are most likely caused by tissue 
sampling bias and selection of specific subclones upon 
engraftment. Occasionally, we observed acquisition of 
additional glioma-specific CNAs in later generations (e.g., 
+Chr16 and −Chr 6 in PDOX T101 G6, Supplementary 
Fig. 2c, online resource; -1p21.1-p31.2 in PDOX P13, Sup-
plementary Fig. 2i, online resource) in line with continu-
ous tumor evolution over time. Of note, these rare events 
occurred in individual tumors and always represented known 
genetic aberrations in gliomas. We did not detect common 
genetic modifications across the cohort which could be 
linked to tumor growth in the mouse microenvironment, 
as has been suggested for subcutaneous PDX [7]. Loss or 
acquisition of new aberrations was much more common 
in cultured GSC lines (Fig. 2e, Supplementary Fig. 2g–i, 
Supplementary Table 3, online resource), including loss of 
EGFR gene amplification and protein expression (Supple-
mentary Fig. 2j, online resource), as noted previously [66].
Fig. 2  Recapitulation of copy number aberrations in PDOXs. a 
Pearson correlation between patient tumors, PDOXs, and cell lines 
derived based on array-CGH genetic profiles (B, patient; X, PDOX; 
C, cell line; adjacent numbers correspond to passage in  vivo or 
in vitro respectively). For statistics see Supplementary Fig. 2b, online 
resource.  b Array-CGH profiles of longitudinal samples (T192-
T233-T251) of patient LIH0192 showing retention of genetic aber-
rations upon recurrence after treatment (radio + chemotherapy). 
The same profiles were recapitulated in PDOXs. c Example of an 
array-CGH profile of a GBM patient and corresponding PDOX 
model (T185 generation 1 and 4). No major changes were detected 
upon serial xenotransplantation. Identical chromosomal breakpoints 
are shown for EGFR amplicon and CDKN2A/B homozygous dele-
tion. See more examples in Supplementary Fig.  2 and Supplemen-
tary Table  3, online resource. d Example of an IDH1mut glioma 
patient and corresponding PDOX and cell line showing high genome 
complexity. Patient was treated with radiotherapy before surgery. e 
Array-CGH profiles of 3 pieces of the same tumor (T16) from patient 
LIH0016 revealing intratumoral genetic heterogeneity (left pan-
els). T16 PDOX and cell line were derived from additional MDM4/
EGFRΔ25-27-amplified clone. Right panels show the different ampli-
cons in patient tumor fragments and PDOX
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PDOXs recapitulate glioma driver mutations 
and genetic heterogeneity
To further assess the mutational content and clonal architec-
ture of patient tissues and matching organoids and PDOXs, 
we applied targeted DNA sequencing to identify rare vari-
ants in disease associated genes using an extended glioma-
specific diagnostic panel (up to 234 genes) [85]. Overall 
the PDOX models showed excellent recapitulation of the 
genetic variants identified in the patient tumors (Fig. 3a, b). 
The rare differences were mainly due to variants detected 
in patient tumors, but not in PDOXs tissues. These ‘lost’ 
variants were situated within chromosome regions deleted 
in the tumor and often had an allele frequency < 50 % (Sup-
plementary Table 4, online resource), suggesting that these 
were germline variants with allelic loss in the tumor and 
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likely originate from normal human tissue (TME) present 
in the patients tumor, but not in the PDOX models. Only a 
handful of genetic variants private to PDOXs were detected 
and nearly all were located in noncoding regions (Fig. 3a, 
Supplementary Table 4, online resource). In comparison, 
PDOX-derived cell lines showed acquisition of further 
new variants in cultures (Supplementary Fig. 3a, online 
resource).
Targeted sequencing confirmed identified copy-number 
alterations and further revealed specific mutations charac-
teristic for gliomas (Fig. 3b, Supplementary Table 5, online 
resource). Assessed IDH1mut gliomas (PDOX and paren-
tal tumor) carried mutations in ATRX and TP53 genes, in 
line with the molecular diagnosis of astrocytomas obtained 
by CpG methylation profiling [20] (Fig. 1b). Digital PCR 
confirmed the presence of wild-type and R132H mutated 
IDH1 alleles in PDOXs, although variations in ratio were 
observed probably due to TME signal in patient tumors and 
tumor aneuploidy (Supplementary Fig. 3b, online resource). 
In line with previous reports [68, 88], in vitro GSC cul-
tures drastically reduced IDH1 wild-type allele frequency in 
T394NS, i.e., cells had lost wild-type IDH1 by passage 10, 
whereas T407NS retained still 20% of the wild-type IDH1 
allele at passage 13. This was combined with an acquisi-
tion of several new variants (Supplementary Fig. 3a, online 
resource). IDHwt GBM PDOXs retained common glioma 
mutations, including EGFR, MDM4, PTEN, PIK3CA, and 
PTCH1 (Fig. 3b). One PDOX (P13) carried an IDH2 mis-
sense mutation (W244R) of unknown significance, which 
has been described in the normal population (rs780131378) 
and is probably a rare private germline variant. It was not 
associated with increased 2HG production (Supplementary 
Table 5, online resource), and thus the tumor was considered 
as IDHwt. The EGFR gene status was remarkably well pre-
served in the PDOXs. EGFR point mutations were detected 
in the extracellular domain (A289T, G598V, F254I, R108K), 
and co-occurred with EGFR amplification. EGFR structural 
variants were present in the extracellular and/or intracellular 
domains, such as Δ2-7 (EGFRvIII), Δ2-15, Δ6-7, Δ14-15 
(EGFRvII), and Δ25-27 (Supplementary Table 5, online 
resource). Notably, in agreement with a previous report [9], 
PDOX P8 displaying EGFR A289T was one of the most 
invasive and proliferative GBM.
In general, our matched longitudinal models retained sim-
ilar coding variants upon recurrence (Fig. 3b). Interestingly, 
LIH0192 patient tumor underwent heterogeneous complex 
structural rearrangements leading to a shift from EGFRvII 
to EGFRvIII upon relapse. These changes led to different 
EGFR protein expression and were retained in the respective 
PDOXs (Fig. 3c, d). LIH0347 patient-derived longitudinal 
PDOXs retained EGFRΔ2-15, which also showed immuno-
reactivity to EGFRvIII antibodies (Supplementary Fig. 3c, 
online resource).
We further used PyClone to follow the clonal dynam-
ics upon engraftment of patient tissues and were able to 
demonstrate that PDOXs retain genetic heterogeneity at 
the subclonal level (Fig. 3e, Supplementary Fig. 3d, online 
resource). Subclonal fractions were also retained in longi-
tudinal models of patients LIH0192 and LIH0347, although 
certain fluctuations in cellular prevalence were observed 
(Fig. 3f, Supplementary Fig. 3e, online resource). Interest-
ingly, we also observed evolutionary dynamics in EGFR 
amplicons (Supplementary Fig. 3f, online resource), aris-
ing most probably from evolutionary trajectories of extra-
chromosomal double minutes [35]. In summary, glioma 
PDOXs largely recapitulate genetic aberrations and genetic 
heterogeneity of the parental tumors. Rare newly acquired 
genetic features in PDOXs recapitulate glioma mutations 
known in patients, suggesting that growth of human tumors 
in the rodent brain can serve as a proxy for ongoing genetic 
evolution in the brain microenvironment. This is in contrast 
to in vitro passaging of glioma cells which regularly leads to 
additional genetic aberrations which are not glioma specific.
Tumor intrinsic epigenetic profiles are preserved 
in PDOXs
Cancer-specific DNA methylation patterns are important 
drivers of gene expression and have been recognized as 
a preferred prognostic biomarker used for brain tumor 
subtyping [20, 22, 79]. Correlation analysis and princi-
pal component analysis (PCA) based on EPIC and 450K 
Illumina DNA methylation arrays showed an overall good 
Fig. 3  Recapitulation of DNA mutations and structural variants in 
PDOXs. a Recapitulation of overall variants determined by targeted 
sequencing. PDOXs were compared to respective patient tumors. 
The number of total variants detected for each patient tumor and 
PDOXs is displayed. b Summary of glioma specific somatic altera-
tions including copy-number changes and mutations in patients and 
their derivative preclinical models. Samples highlighted in gray rep-
resent longitudinal PDOXs. c Example of longitudinal GBM samples 
(T192-T233-T251) of patient LIH0192 showing altered clonal dis-
tribution of EGFR structural variant vII to vIII upon relapse, which 
is recapitulated in the respective PDOXs. Distinct EGFR genomic 
regions deleted in respective variants are depicted. d Western blot 
against EGFR (cocktail antibody recognizing wild-type (wt) and 
structural variants) confirms protein expression of EGFRwt as well 
as the respective structural variants EGFRvII (in T192) and vIII (in 
T251) with decreased molecular weight. U87 cells overexpress-
ing EGFRwt and EGFRvIII are shown for size reference. e Cellular 
prevalence estimates from PyClone representing clonal populations 
detected in longitudinal patient tumors and respective PDOXs. Exam-
ples shown for T192 and T251. Each cluster of mutations was com-
putationally inferred to reflect a subclone. Number of genetic variants 
contributing to each clone is depicted. f Cellular prevalence estimates 
from PyClone representing clonal subpopulations detected in longitu-
dinal patient LIH0192 and its respective PDOXs. Each line represents 
a cluster of mutations computationally inferred to reflect a subclone. 
Only genetic variants detected in all samples were considered for 
analysis
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correlation between patient tumors and PDOXs (Fig. 4a, 
Supplementary Fig. 4a, online resource), where samples 
clustered based on IDH status. Although sample type also 
contributed to the source of variation in the cohort, the 
IDH status was the main source of variation (Supplemen-
tary Fig. 4b, online resource). IDH1mut gliomas displayed 
Fig. 4  DNA methylation profiling. a Pearson correlation of DNA 
methylation profiles between glioma patient samples, PDOXs and 
cell lines derived thereof based on 450 k and EPIC arrays (B, patient; 
X, PDOX; C, cell line, overlapping regions between arrays only). 
For statistics see Supplementary Fig.  4a, online resource. b Global 
beta-value distributions are very similar between patient samples 
and PDOXs. Cell lines displayed an increased DNA methylation at 
open sea, shelf, and shore regions. c Beta-value distributions are very 
similar upon tumor recurrence and are recapitulated in correspond-
ing PDOXs. Examples are shown for longitudinal samples of patients 
LIH0192, LIH0347, and LIH0394, the latter being IDH1mut. d Mean 
beta-value distribution in patients and PDOXs show increased meth-
ylation in a subset of CpG islands and decreased methylation of til-
ing regions in PDOXs. CpG sites with FDR < 0.05 are displayed in 
red, remaining probes are shown in blue. e Examples of hypo- and 
hypermethylated CpG islands in PDOXs. GFAP is widely expressed 
in GBM, whereas IRF6 is involved in innate immune response. Dif-
ferentially methylated sites are changing from hemi-methylated in 
patient tumors to either unmethylated (GFAP) or methylated (IRF6) 
status in PDOXs
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divergent DNA methylation of specific CpG islands com-
pared to IDHwt gliomas (Supplementary Fig. 4c, online 
resource). Yet, G-CIMP-low subtype dominated our IDH-
1mut patient tumors and PDOXs (Supplementary Table 6, 
online resource), presumably in line with their increased 
aggressiveness [33]. The beta-value distributions were 
very similar between PDOXs and parental tumors, whereas 
GSC lines displayed increased DNA methylation at open 
sea, shelf, and shore genomic regions (Fig. 4b). This was 
supported by PCA analysis showing a lower similarity 
of GSC lines to patient tumors in comparison to PDOXs 
(Supplementary Fig. 4a, online resource). This was true 
for IDH1wt and mutated cell lines (Supplementary Fig. 4a, 
d, online resource). Importantly, the MGMT promoter 
DNA methylation status was preserved between PDOX 
and parental tumor in all but two PDOXs (Supplementary 
Table 6, online resource). Global DNA methylation pro-
files based on beta-value distributions were also well pre-
served in longitudinal glioma samples between each other 
and with their respective PDOXs. Overall, most tumors 
retained the same DNA methylation profile upon recur-
rence (Fig. 4c), including MGMT promoter methylation 
status (Supplementary Table 6, online resource), although 
differences at individual CpG sites are possible.
Statistical analysis of paired methylation profiles revealed 
only minor changes between patient tumors and respective 
PDOXs (Limma, FDR < 0.01). Only 35 individual CpG sites 
showed differences in mean methylation beta values above 
0.4, corresponding to an essential switch in DNA methyla-
tion status, but none were gene annotated CpGs. A partial 
change of DNA methylation levels (beta value difference 
0.2–0.4) was observed at CpG sites of 226 CpG islands, 
89 promoters, 74 gene bodies and 943 tiling regions. Most 
sites that were demethylated in PDOX corresponded to tiling 
regions that changed from hemi- to unmethylated (894/943, 
Fig. 4d), pointing towards global hypomethylation charac-
teristic for high-grade glioma [22]. This was also true for 
certain gene promoters specific to GBM cells (e.g., GFAP, 
Fig. 4e). An increase towards fully methylated CpG sites 
was observed typically at CpG islands (196/226, Fig. 4d), 
including promoters of genes expressed classically by the 
TME (e.g., IRF6 for immune cells, Fig. 4e), reflecting the 
impact of non-neoplastic cells on methylation profiling [56]. 
Accordingly, the molecular classification based on previ-
ously defined DNA methylation classes [20, 22, 33] was 
well retained in PDOXs (Fig. 4a, Supplementary Table 6, 
online resource). Class switches between patient and PDOX 
occurred from mesenchymal-like to classic-like tumors 
(LGm5 to LGm4, mesenchymal to RTK II class, Supple-
mentary Table 6, online resource), in line with the influence 
of the TME on DNA methylation profiles as has also been 
shown for gene expression signatures [112]. GSC cell lines 
displayed more divergent DNA methylation profiles with 
increased DNA methylation levels (Fig. 4a, b) and were not 
clearly classified (Supplementary Table 6, online resource). 
Although we did not detect a link between treatment history 
of patient tumors and molecular subtypes, more data will 
be required in the future to perform meaningful statistical 
analyses.
Gene expression analysis reveals close resemblance 
between patient tumors and PDOXs
To determine to what extent gene expression profiles of 
parental tumors are retained in glioma PDOXs, we per-
formed genome-wide transcript analysis using human-
specific microarrays (Fig. 5a). In parallel, we analyzed cell 
cultures and corresponding intracranial xenografts from 
GSC (NCH421k, NCH644) and adherent cell lines (U87, 
U251). Unsupervised hierarchical cluster and PCA analy-
ses revealed close resemblance of PDOXs to corresponding 
patient tumors, although higher similarity of samples of the 
same type was observed (Fig. 5a, Supplementary Fig. 5a, 
online resource). Cell lines and their xenografts were more 
dissimilar and clustered according to their origin, in line 
with a higher cellular selection and adaptation in long term 
in vitro cultures. Transcriptomic profiles of PDOXs also dis-
played strongest similarity to GBMs from the TCGA cohort 
[19] (Supplementary Fig. 5b, online resource). Analysis of 
transcriptomic subtypes revealed differences when using 
the original molecular signatures proposed by Verhaak 
et al. [107]. However, with the recent tumor-intrinsic clas-
sification aimed at reducing the influence of TME [112], 
the subtyping remained constant (Supplementary Table 7, 
online resource), suggesting that transcriptomic differences 
between patient tumors and PDOXs arise from TME-asso-
ciated gene expression. Cell lines retained transcriptomic 
subtypes were retained upon in vivo growth. Analysis of 
differentially expressed genes between PDOXs and parental 
tumors (2-way ANOVA, FDR<0.01, absFC≥2) revealed an 
increase in tumor intrinsic signals such as cell cycle and 
DNA repair (Fig. 5b), which was most prominent in highly 
proliferative PDOXs (P3, P8, P13, Fig. 5c). Genes down-
regulated in PDOXs were associated with TME processes, 
i.e., immune response, angiogenesis and macrophage activa-
tion (Fig. 5b, c). Specific markers of human TME compo-
nents such as endothelial cells (VWF, KDR), microglia/mac-
rophages (ITGAX, AIF1, CD68), pericytes/vascular smooth 
muscle cells (PDGFRB, ACTA2) and hematopoietic cells 
(CTLA4, CD4, PTPRC) were depleted in PDOXs (Fig. 5c). 
This included also ABCB1 and ABCG2, which we have pre-
viously shown to be restricted to brain endothelial cells in 
human GBM [47]. The general depletion of human TME 
transcriptome upon xenografting was confirmed by inde-
pendent component analysis (Fig. 5d) and flow cytometry 
(Fig. 5e). Interpatient differences were retained in PDOXs, 
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e.g., EGFR expression was maintained at similar levels as 
in patients (Fig. 5c). We did not detect an upregulation of 
specific molecular pathways linked to stemness (i.e., can-
cer stem-like profiles), confirming the lack of a particular 
selection for tumor subpopulations. Indeed, the heteroge-
neous expression of stem cell markers in GBM, as previ-
ously reported [36], was retained in the respective PDOXs 
(Fig. 5e) and remained largely stable over serial transplan-
tations (Supplementary Fig. 5c, online resource). Tran-
scriptomic analysis at the single cell level revealed similar 
proportions of cycling cells and the presence of a hypoxic 
gradient in PDOX (Fig. 5f) as shown for GBM patients [81]. 
PDOXs also recapitulated intratumoral heterogeneity and 
phenotypic cellular states previously described in GBM 
patients [77, 112] (Fig. 5g). Mouse-derived TME, which 
replaced human TME, showed similar cellular subpopu-
lations as detected in patient tumors including microglia/
macrophages, oligodendrocyte progenitor cells (OPCs) and 
astrocytes comparable to human GBM TME [31] (Supple-
mentary Fig. 5d, online resource). In conclusion, our data 
show that glioma PDOXs recapitulate well tumor-intrinsic 
transcriptomic profiles. Differences in gene expression sig-
natures at the bulk level can be explained by the replace-
ment of the human TME by mouse cells undergoing GBM-
specific adaptation.
Preclinical drug testing in PDOX‑derived 
standardized 3D glioma organoids provides 
clinically relevant outcomes
The PDOX cohort described above constitutes a living 
biobank maintained by serial transplantation of organoids 
obtained through mechanical cutting of tumor tissue. This 
allows to expand the patient tumor in its natural brain 
microenvironment, generating sufficient material for large 
scale preclinical drug testing. To this aim, we standard-
ized the derivation of uniform GBM organoids amenable 
for reproducible drug screening. Organoids were generated 
from 1000 MACS-purified single tumor cells obtained from 
PDOXs, which were able to self-organize into 3D organoids 
within 72h in nonadherent conditions (Fig. 6a). This allowed 
for sensitive evaluation of cell viability and toxicity in a 384-
well plate format (Supplementary Fig. 6a, online resource), 
similar to protocols described for other types of cancer 
organoids [44]. To assess whether PDOX-derived organoids 
recapitulate known mechanisms of drug sensitivity and 
achieve clinically relevant responses, we subjected a cohort 
of 18 GBM PDOXs to temozolomide (TMZ), the standard 
DNA-alkylating agent in clinical practice. Cell responses 
were calculated as the Area Under the Curve (AUC). In 
accordance with clinical data, GBM organoids showed only 
a partial response to TMZ (AUC 200-600, Fig. 6a, b, Sup-
plementary Fig. 6b, online resource). Importantly, tumors 
with a methylated MGMT promoter appeared less resistant 
in comparison to MGMT promoter-unmethylated GBMs 
(Fig. 6c, Supplementary Fig. 6b, online resource). No dif-
ferential response was observed between treatment-naïve 
organoids and organoids derived from patients previously 
exposed to chemoradiotherapy (Supplementary Fig. 6c, 
online resource).
Dianhydrogalactitol (VAL‑083) exhibits strong 
efficacy against GBM independent of (epi)genetic 
background and treatment history
We further tested dianhydrogalactitol (VAL-083), a 
bifunctional compound able to alkylate  N7-guanine and 
form interstrand crosslinks and DNA double strand breaks 
[117]. VAL-083 is known to penetrate the blood–brain 
barrier and to accumulate in the cerebrospinal fluid and 
brain parenchyma [39]; it is currently tested in clinical tri-
als for recurrent GBM (NCT02717962) as well as for treat-
ment-naïve MGMT promoter unmethylated GBM patients 
(NCT03050736). In our cohort, VAL-083 was significantly 
more effective than TMZ (Fig. 6a, b) and the response 
was not dependent on MGMT promoter methylation sta-
tus (Fig. 6c). The response was similar in treatment-naïve 
and relapsed organoids (Supplementary Fig. 6c, online 
resource), suggesting that VAL-083 is able to overcome 
TMZ resistance. In view of the strong efficacy of VAL-083 
in the ex vivo assay we evaluated its ability to decrease 
tumor growth in vivo. Due to the structural similarity with 
glucose, we hypothesized that uptake of VAL-083 could 
be further enhanced under hypoxia; we therefore also 
applied a combination treatment with the antiangiogenic 
agent Bevacizumab previously shown to induce hypoxia 
in GBM [1, 53]. As expected, Bevacizumab treatment 
Fig. 5  Transcriptomic profiles and intratumoral heterogeneity. a Pear-
son’s correlation indicating similarity of genome-wide gene expres-
sion profiles between normal human brain, glioma patient samples, 
PDOXs, GSC lines (NCH421k, NCH644) and classical glioma 
lines (U87, U251) grown in vitro or as xenograft (‘X’). Human spe-
cific arrays were applied for transcriptome analysis. b Summary 
of main GO terms characterizing genes differentially present in 
PDOXs (FRD  ≤  0.01, ab(FC)  ≥  2, Limma). c Heatmap represent-
ing gene expression levels for a selection of classical TME and cell 
cycle markers in normal brain (NB), patients and respective PDOXs. 
d Independent component analysis showing depleted transcriptomic 
signals associated with immune response and neuronal ensheathment 
in PDOXs and cell lines. Cell cycle independent component (IC) was 
the highest in PDOXs and cell lines, cell migration-associated IC 
was the highest in patients and PDOXs. e Flow cytometric analysis 
to detect human cell subpopulations in patient samples and respective 
PDOXs. Examples are shown for PDOX T331 expressing EGFR in 
tumor cells. f Single cell signatures showing the presence of human 
tumor cells in distinct phases of cell cycle and hypoxic gradient in 
PDOXs. g Assessment of GBM cellular states [77] and TCGA GBM 
subtypes [112] at single cell level in PDOX tumor cells
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did not halt tumor progression despite decreased contrast 
enhancement on MRI (Fig. 6d) and blood vessel normali-
zation (Supplementary Fig. 6d, online resource). VAL-083 
monotherapy led to a dramatic reduction in tumor growth 
(Fig. 6e), an effect which was only mildly accentuated by 
combined treatment. Histological assessment of tumor-
containing brains confirmed the strong reduction in tumor 
volume upon VAL-083 treatment (Supplementary Fig. 6e, 
online resource). This was paralleled by an increase in 
DNA damage in tumor cells, determined by H2AX phos-
phorylation (H2AX-P) (Supplementary Fig. 6f, online 
resource). Limited H2AX-P was also seen in normal brain 
cells close to the meninges and the subventricular zone, 
but to a much lower extent than in tumor cells. In sum-
mary, we show that VAL-083 has a consistently favorable 
drug profile against GBM; thus, representing a promising 
candidate for GBM treatment either alone or in combina-
tion with antiangiogenic compounds.
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PDOX‑derived organoids are amenable 
to high‑throughput drug screening for precision 
medicine
To evaluate the potential for personalized treatment regimens 
of our models, we functionally assessed the response against 
a set of EGFR/ErbB small-molecule tyrosine kinase inhibi-
tors (Erlotinib, Gefitinib, AZD3759, AG490, and Daphtenin) 
and CDK4/6 inhibitors (Abemaciclib, Palbociclib) with var-
ying specificity in 16 PDOX-derived organoids with variable 
genetic makeup of these pathways. The inability to preserve 
gene amplification and EGFR structural variants in most cell 
culture models including GSCs [66], did so far not allow 
for accurate personalized preclinical studies. Our testing 
group included GBM with different status of CDK4, CDK6, 
and EGFR amplification, EGFR genetic variants and point 
mutations (Fig. 3b, Supplementary Table 5, online resource). 
The responses against EGFR inhibitors were highly variable 
across patient organoids (Fig. 6f, Supplementary Fig. 6g, 
online resource). In contrast to kinase domain mutations 
found in lung cancer, glioma-specific extracellular domain 
mutants are known to respond poorly to EGFR inhibitors 
[64]. Still, we found that GBMs carrying EGFR mutations, 
except for EGFR F254I (PDOX T434), were more sensitive 
to Erlotinib and AZD3759, but not to the other EGFR inhibi-
tors, Gefitinib, AG490 and Daphtenin (Fig. 6f and Supple-
mentary Fig. 6g, online resource). This is in accordance with 
the fact that EGFR R108K, G598V, and A289T are missense 
mutations leading to a gain-of-function, shown previously to 
sensitize tumors to Erlotinib [63]. The role of EGFR F254I 
is currently unclear. EGFR amplification and corresponding 
high protein expression also had an impact on the sensitivity 
to Erlotinib and AZD3759, where nonamplified tumors with 
low protein expression were most resistant. EGFR structural 
variants did not sensitize tumors in our cohort to any of the 
five compounds. Similarly, tumors carrying CDK4 (PDOX 
T434) and CDK6 (PDOX T341) amplification were most 
sensitive to CDK4/6 inhibitors Palbociclib and Abemaciclib 
(Fig. 6g).
Finally, we performed a proof-of-concept study on 
PDOX-derived organoids for high-throughput drug screen-
ing using the cell printing technology based on the ASFA 
Spotter ST [37]. PDOX T434 derived GBM cells were dis-
pensed onto pillars (1000 cells per pillar), embedded into 
alginate drops and allowed to reform 3D organoids (Fig. 6h). 
A library of 42 FDA-approved drugs was then applied for 7 
days and response was assessed via a High Content imag-
ing system (CV 8000) recognizing viable cells. To select 
the strongest hits, we applied normalized AUCs (Z score, 
− 1 threshold) [64]. The screen showed similar responses as 
the 384-well plate protocol (Supplementary Fig. 6h, online 
resource), and confirmed sensitivity of T434 tumor cells to 
Abemaciclib and resistance to Erlotinib and Gefitinib. Inter-
estingly, it revealed sensitivity to several other inhibitors, 
including Afatinib,—a second-generation EGFR inhibitor. In 
summary, we show that PDOX-derived GBM organoids dis-
play clinically relevant drug responses and can be applied for 
personalized drug screening in a high-throughput manner.
Discussion
Although major discoveries can be performed directly on 
patient tumors, biological material is restricted, gener-
ally limiting such studies to descriptive analyses and low-
throughput preclinical assays. Here we present a living 
tumor biobank that encompasses the clinical diversity of 
high-grade diffuse gliomas. Over 160 organoids and 40 
PDOX models were established from treatment-naïve gli-
oma patients and patients that underwent standard-of-care, 
of which 15 represent paired longitudinal models. Glioma 
organoids grown in PDOX, combines the generation of a 
Fig. 6  Drug response assessment in glioma organoids and PDOXs. 
a Drug response was evaluated in PDOX-derived organoids with 
standardized size (green,  viable; red, dead cells). Representative 
images are shown for TMZ and VAL-083 treatment of T434-derived 
organoids. Scale bar = 50 µm. b Quantification of AUC upon expo-
sure to TMZ and VAL-083. Mean AUC  ±  SEM is shown for each 
model. Experiment was performed once with three technical rep-
licates per PDOX per drug concentration. VAL-083 is generally 
more effective in PDOX-derived organoids in comparison to TMZ 
(***pvalue < 0.001, unpaired t test). c Mean AUC upon exposure to 
TMZ and VAL-083 in MGMT promoter methylated and unmeth-
ylated tumors. Tumors with methylated MGMT promoter show 
enhanced response to TMZ, while response to VAL-083 is inde-
pendent of the MGMT promoter status (**pvalue  <  0.01, unpaired t 
test). d PDOX T16 treated in vivo with VAL-083, Bevacizumab or 
a combination. Tumor progression was assessed by T1-weighted 
and T2-weighted MRI images (n = 6–7 mice per group) prior treat-
ment (day 35) and post treatment (day 49 and 56 equivalent of 14 
and 21 days since beginning of treatment respectively). e Assess-
ment of tumor progression over time reveals significant reduction of 
tumor growth upon VAL-083 treatment. Tumor growth rate between 
treatment groups was calculated during the entire study (day 35 vs. 
day 56, n  =  6–7, ***pvalue  <  0.001, **pvalue  <  0.01, ANOVA with 
Tukey’s Multiple Comparison Test). f Quantification of AUC upon 
exposure to EGFR inhibitor Erlotinib showing higher sensitivity in 
EGFR mutated tumors (vs EGFR wild type) and in EGFR amplified 
tumors (vs EGFR nonamplified). This is also recapitulated at the level 
of EGFR protein expression. No significant effect is seen for tumors 
with or without EGFR variants. (*pvalue < 0.05, unpaired t test); wt, 
wild type; mut, mutated; Amp, amplified; SV, structural variant; 
EC, extracellular domains; IC, intracellular domains; exp, expres-
sion. g Quantification of AUC upon exposure to CDK4/6 inhibitors 
Palbociclib and Abemaciclib shows higher sensitivity of CDK4 and 
CDK6 amplified tumors (vs nonamplified tumors). (*pvalue  <  0.05, 
**pvalue < 0.01, unpaired t test). For f–g experiments were performed 
twice with 3 technical replicates each. See Supplementary Table  8 
for mean AUC ± SEM. h High-throughput screening with 42 FDA-
approved drug library in PDOX T434. Drug response data are dis-
played as normalized AUC +/−SEM, (n = 2), ‘−1’ value is indicated 
as a threshold for strongest hits
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powerful in vivo model for precision oncology with the 
expansion of patient tumor material in an appropriate TME 
setting not possible in vitro. Our PDOX cohort contains 
tumors of varying genetic and molecular background, and 
represents a unique tool for drug screening, functional stud-
ies and in vivo drug efficacy studies. We show that glioma 
PDOXs recapitulate (1) glioma tissue architecture, including 
features of angiogenesis and invasion, (2) genetic variants 
and CNAs, including rare gene amplifications (3) epigenetic 
and transcriptomic tumor intrinsic signatures, (4) intratu-
moral genetic, transcriptomic, and stem-cell-associated 
heterogeneity, (5) clinically relevant drug responses. Our 
models and associated molecular data are openly shared and 
available at the PDXFinder portal (https ://www.pdxfi nder.
org/) and via the EurOPDX consortium (https ://www.europ 
dx.eu/). They represent a robust tool for reliable expansion 
of patient tumor material while maintaining close identity 
with the parental tumors, allowing for high-throughput drug 
testing and precision medicine.
Most available glioma PDX models are established and 
maintained through subcutaneous implantation of tumor 
fragments [21, 106], where the long term impact of a non-
brain TME is unclear. Orthotopic GBM xenografts usually 
rely on single cell dissociation followed by in vitro cultures 
as GSCs (BTICs) prior to xenotransplantation [21, 35, 49, 
52, 108], where cultures are often maintained for unspeci-
fied time and passage number. To minimize the loss of tissue 
architecture and clonal heterogeneity, we use organoids from 
mechanically minced glioma tissue, only briefly maintained 
in culture without any in vitro passaging. In order to main-
tain the heterogeneous nature of the primary tumor within 
self-organizing organoids, we did not try to achieve indefi-
nite growth of organoids in vitro [49, 51], instead we ortho-
topic xenografting for tissue expansion and maintenance. 
We find that most GBMs and lower grade gliomas give rise 
to short-term organoids. Successful PDOX establishment 
enriches for high-grade tumors, including IDHwt GBMs and 
IDH1mut gliomas grades III and IV. This is in concord-
ance with the general selection of aggressive tumors upon 
PDX generation in different tumor types, including pediatric 
brain tumors [13]. So far, only a handful of IDH1mut gli-
oma models have been described, which all suffer from poor 
reproducibility, a long development time and/or changes in 
IDH1 status [55, 69, 75, 99, 106, 109]. Successful IDH-
1mut models in our cohort were defined molecularly as high-
grade astrocytomas with abundant chromosomal aberrations, 
CDKN2A/B loss, ATRX, and TP53 mutations and G-CIMP-
low signature. These molecular features correspond to the 
most aggressive IDH1mut gliomas [5, 33, 109]. Importantly, 
our models retain R132H IDH1 heterozygosity and efficient 
production of 2HG [43]. In vitro cultures derived from these 
tumors either died or led to depletion of the wild-type IDH1 
allele, in line with previous reports [68, 104], suggesting that 
IDH1mut gliomas require components of the brain microen-
vironment to maintain their growth. Importantly, our fully 
annotated cohort displays a wide variety of genetic features 
not recapitulated in other models (e.g., EGFR and PDGFRA 
amplification), thus reflecting the wide interpatient hetero-
geneity of high-grade gliomas. Our PDOX biobank also 
contains 15 unique paired models derived from the same 
patients at initial diagnosis and upon disease relapse.
The recapitulation of histopathological features of glio-
mas has been challenging with classical serum-grown cell 
lines, as they largely lose the characteristic invasive potential 
of diffuse gliomas upon xenotransplantation [28, 71]. Infil-
trative growth is maintained in all our PDOXs, although the 
extent of typical glioma features, including invasion, angio-
genesis, and proliferation rate can greatly vary across mod-
els, likely reflecting interpatient heterogeneity. We find that 
prominent angiogenic features along with pseudopalisading 
necrosis are rare in mice compared to rats, which may arise 
from differences in brain size and/or in molecular interaction 
between species. This suggests that for studies addressing 
aspects of angiogenesis, hypoxia, and blood–brain barrier, 
rat PDOX models may be more appropriate. Others have 
also reported gradients of invasive and angiogenic features 
across GBM xenografts, with limited endothelial prolifera-
tion and necrosis in mouse brains [106, 109], while large 
subcutaneous tumors display extensive angiogenesis [106].
We have previously shown that GBM organoids and cor-
responding PDOXs faithfully retain tumor cell ploidy [92]. 
Here we demonstrate that glioma organoids and PDOXs 
accurately maintain distinct genetic backgrounds of parental 
tumors, including gene amplifications of EGFR, PDGFRA, 
MET, MDM2/4, and CDK4/6, which are difficult to derive 
and preserve in vitro [66, 88]. PDOXs also recapitulate com-
plex EGFR variants and mutations present concomitantly 
with EGFR amplification. At scale, we found that individual 
genomic profiles are highly conserved in PDOXs. We did not 
detect major divergences in CNAs as reported for subcutane-
ous GBM PDXs [7]. The difference in results may be related 
to the subcutaneous transplantation, which may lead to a 
different tumor evolution than in the brain. Alternatively, it 
may be due to differences in data analysis, since array-CGH 
based CNA determination, employed by us, is known to be 
more accurate than CNAs inferred from gene expression 
profiles [115]. We further observed extensive preservation of 
genetic intratumoral heterogeneity, although some fluctua-
tions in subclonal architecture were detected. Interestingly, 
we report a case of EGFR variant selection, observed both 
upon tumor relapse in patients as well as upon xenografting. 
This may be linked to high levels of EGFR amplification and 
the presence of extrachromosomal double minute structures, 
which are known to show evolutionary dynamics [35].
In rare cases PDOX models showed engraftment or 
expansion of specific genetic clones, with distinct gene 
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amplifications or mutations, differing from the originating 
tumor. Genomic events that were private to the PDOX cor-
respond to classical glioma aberrations, known to be hetero-
geneous late events in GBM [54, 96], supporting the notion 
that the PDOX-dominating clones were a result of original 
intratumor heterogeneity revealed by sampling and natural 
glioma evolution over time. In contrast to a previous analysis 
of subcutaneous PDX [7], we did not detect any recurrent 
genetic changes across the cohort suggesting that the interac-
tion of human tumor cells with mouse TME does not influ-
ence genetic features of the tumor per se. Minor changes in 
clonal trajectories have also been observed in certain PDX 
from GBMs [106], brain metastases [101] and other cancers 
[40, 46]. In this respect, PDOX models can be considered as 
a proxy for dynamic clonal evolution, which is difficult to 
measure in patients. We also did not observe major changes 
in paired longitudinal glioma samples neither in the parental 
patient tumor nor in the corresponding PDOX, in accord-
ance with limited treatment-induced clonal evolution in dif-
fuse gliomas [5]. We report a case of clonal evolution from 
EGFRvII to EGFRvIII, which was recapitulated in the cor-
responding PDOXs. Although EGFRvIII may be lost upon 
recurrence, cases with acquisition of this variant were also 
reported [38, 110]. Interestingly, longitudinal models also 
retained state-specific intratumoral heterogeneity and genetic 
subclones, highlighting the notion that these unique matched 
PDOXs provide an ideal platform to study specific molecular 
events in initial and recurrent disease side by side. We fur-
ther show that propagation of GBM cells grown as GSCs in 
vitro leads to a faster genetic drift, including ploidy changes, 
and acquisition of new CNAs and genetic variants.
At scale tumor-intrinsic epigenetic and transcriptomic 
profiles of individual tumors were well recapitulated in 
PDOX. Our PDOX cohort represents diverse molecular sub-
types and retains intratumoral heterogeneity and plasticity, in 
particular, we show that GBM PDOX display cellular state 
transitions recently described in patient samples [77]. No 
major molecular changes or selection of cellular subpopula-
tions were detected, except for those related to the replace-
ment of human TME by mouse counterparts. These changes 
are expected in bulk tissue analyses where methylation and 
transcriptome profiles are biased by TME-derived signals 
[56, 112]. In line with the previous reports [6, 88] in vitro 
cell lines showed increased global DNA methylation levels 
and more profound changes in transcriptomic profiles.
Limitations of PDOX models include possible inter-
species differences at the molecular level and the lack of a 
complete immune system in immunocompromised animals. 
While the adaptive immune system is largely absent in these 
mice, they retain a largely functional innate immune sys-
tem, including microglia, the brain resident immune effec-
tor cells, and peripheral myeloid cells. GBM are largely 
lymphocyte depleted tumors[102], while microglia and 
macrophages constitute the major immune component [82]. 
Here we show that classical glioma TME components such 
as microglia/macrophages, astrocytes, and OPCs are present 
in xenografted tumors, indicating that tumor cell interactions 
with the TME remain active in PDOX. Of note, we observe 
a similar transcriptomic shift in tumor-associated micro-
glia/macrophages as described in GBM patients [31, 113]. 
It remains to be determined to what extent these models will 
be amenable to immunotherapeutic studies targeting tumor-
associated microglia/macrophages. Although challenging, 
adaptation of glioma PDOXs to a humanized background 
might be possible and/or studies in an immunocompetent 
context could be performed with PDOX-derived organoids 
co-cultured with autologous immune cells.
Other drawbacks of patient-derived (orthotopic) xeno-
grafts, include high costs, complex logistics and an inherent 
low-throughput nature. Large-scale in vivo screens are possi-
ble; however, they are laborious and require specific statisti-
cal settings [46]. Expansion of human gliomas in PDOX and 
initial drug screens performed on PDOX-derived organoids 
appears as a good compromise between retention of glioma 
hallmarks and a cost-effective drug testing pipeline. In con-
trast to patient-derived short-term cultures and organoids 
[51, 64], it allows for tumor expansion and in vivo valida-
tion. We have developed our protocols to reconstitute 3D 
organoids of equal size, which allow for reproducible drug 
testing. Downscaling of cell number per organoid facilitated 
drug delivery, viability detection, and upscaling to high-
throughput screens. These protocols can also be adapted to 
reintroduce TME components [12] and immune cells. We 
show that PDOX-derived organoids show clinically relevant 
responses: (1) organoids with MGMT promoter methylation 
showed higher sensitivity to TMZ, (2) CDK4/6 amplified 
organoids responded better to CDK4/6 inhibitors, (3) orga-
noids carrying EGFR R108K, G598V, and A289T gain-of-
function mutations were most sensitive to Erlotinib and 
AZD3759, whereas EGFR low tumors were most resistant. 
Although EGFRvIII [73] and deletions in the C-terminal 
domain (Δ25-27/28) were shown to sensitize GBM cells to 
Erlotinib [25], none of the EGFR structural variants pre-
sent in our testing group systematically sensitized tumors 
to any of the EGFR inhibitors. Of note, the tested organoids 
displayed PTEN loss, a known resistance factor leading to 
dissociation of EGFR inhibition from downstream PI3K 
pathway inhibition [73]. Remarkably, VAL-083 showed a 
significantly better response than TMZ against GBMs of dif-
ferent genetic backgrounds and irrespective of MGMT status. 
VAL-083 was able to overcome TMZ resistance in recurrent 
GBM and its efficacy was confirmed in vivo, with no toxicity 
observed, lending optimism to ongoing clinical trials.
Overall, our glioma PDOX cohort provides a powerful 
platform for understanding tumor biology and preclinical 
treatment interventions at the individual patient level. So 
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far, the co-clinical use of glioma PDOXs as patient avatars 
for treatment prediction remains challenging as in most 
cases the time to establish PDOXs in sufficient quantity 
required for preclinical drug testing (generation 2-3) takes 
longer than the survival of most high-grade glioma patients. 
Instead, PDOXs can play a key role as a preclinical platform 
in ‘mouse clinical trials’ [114] for personalized medicine 
regimens. Organoid cultures are further an excellent tool 
for high-throughput drug intervention studies at lower cost 
and can be used directly either established from the patient 
tumor tissue or from PDOXs. Longitudinal models further 
constitute a robust tool for the analysis of tumor evolution 
and resistance mechanisms following targeted or untargeted 
treatments. By sharing the models and molecular data, we 
aim to facilitate large collaborative future preclinical trials.
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